text:
Scott M. Hammer
Karen Brudney
Mary Ann Chiasson
Phyllis Della-Latta
Jay Dobkin
E. Yoko Furuya
Peter Gordon
Rachel Gordon
Sandra Hyman
Jessica Justman
Charles Knirsch
Christine J. Kubin
Franklin Lowy
Wendy McGahee Benjamin Miko
Ellen Morrison
Julie Myers
Susan Olender
Marcus Pereira
Deborah Rudin
Noga Shalev
Van Tieu
Anne-Catrin Uhlemann
Scott M. Hammer, MD
Chief, Division of Infectious Diseases
Harold C. Neu Professor of Medicine
Professor of Epidemiology
Columbia College, BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972
SPECIALTY: HIV pathogenesis, therapy, and vaccine development
Dr. Hammer is the Harold C. Neu Professor of Medicine, Professor of Epidemiology and Chief of the Division of Infectious Diseases at the NewYork-Presbyterian/Columbia University Medical Center (NYP-CUMC). Dr. Hammer's major investigative interest is the treatment and prevention of HIV disease. He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG), a multicenter organization which performs clinical trials designed to improve the understanding and treatment of HIV infection and its complications. As an ACTG investigator, Dr. Hammer chaired the two largest national trials of antiretroviral therapy carried out by that group in the 1990's, studies which contributed to the current standard of care of HIV infection. In addition to his interest in the treatment of persons with established HIV infection, Dr. Hammer is an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine. He is the current protocol chair of HVTN 505, an advanced phase II study of the preventive HIV vaccine regimen developed by NIAID's Vaccine Research Center. He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine. Dr. Hammer is a former Chair of the International AIDS Society-USA's Antiretroviral Guidelines Panel and former Vice Chair of the World Health Organization's Strategic and Technical Advisory Committee for HIV/AIDS. He chaired the Guidelines Development Group of the WHO's Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO's Global HIV Drug Resistance Surveillance Program. In his role as Chief of the Division of Infectious Diseases at CUMC, he is dedicated to fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.
Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25;308(4):387-402.
Hammer SM. Antiretroviral treatment as prevention. N Engl J Med. 2011 Aug 11;365(6):561-2.
Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One. 2011 Apr 13;6(4):e18526.
Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis. 2011 Apr 1;203(7):969-75.
Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team. Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum Retroviruses. 2010 Nov 23.
Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 Jul 21;304(3):321-33.
Montaner JS, Richman DD, Hammer SM; International AIDS Society-USA Antiretroviral Guidelines Panel. Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis. 2009 Oct 15;49(8):1283-4.
Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, Brechtl J, Hammer SM. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol. 2009 Aug;81(8):1323-35.
Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L. Persistent minority K103Nmutations among women exposed to single-dose nevirapine and virologic response tononnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15;48(4):462-72.
Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC. HIV vaccine research: the way forward. Science. 2008 Jul 25;321(5888):530-2.
Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25
Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA:Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel.JAMA 2008; 300:555-570.
Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM and Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-285
Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM:The challenge of HIV-1 subtype diversity.NEJM 2008;358:1590-1602.
Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.
Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.
Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.
Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.
Hammer SM, Mofenson L, Havlir D, Vitorio M, PerriensJ and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int.
Hammer SM, Bassett R, Squires KE, Fischl M, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, and DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8:507-518.
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, and Mellors JW (for the AIDS clinical trials group 398 study team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc. 2002;288:169-180.
Hammer S, Gibb D, Havlir D, Mofenson L, VAn Beek I, Vella S, Vareldzis B, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. World Health Organization, April 2002, available at www.who.int.
Hammer SM. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-2023.
Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.
Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (for the AIDS clinical trials group 320 study team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (for the ACTG 175 study team). A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-sponsored AIDS clinical trials group study 175. N Engl J Med. 1996;335:1081-1096.
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: (212) 305-7185
Fax: (212) 305-7290
E-mail: firstname.lastname@example.com
Back to Top
NAME: Karen Brudney, MD
Assistant Clinical Professor of Medicine
Yale University, BA, 1973
Columbia University College of Physicians and Surgeons, MD, 1980
SPECIALTY: Tuberculosis, HIV therapy, HIV primary care, patient adherence and access to care
Dr. Brudney is the director of the Infectious Disease/AIDS Clinic and the
director of TB service at NewYork–Presbyterian Hospital. She is also the
program director for the Treatment Adherence Demonstration Project. In
order to improve antiretroviral adherence in difficult populations, an
interdisciplinary program called Jumpstart was initiated in 1998 in the
Infectious Disease/AIDS Clinic at NewYork–Presbyterian Hospital. Results
from this successful program are currently being analyzed. Dr Brudney is
also the recipient of a Fogarty Award for AIDS International Training and
Research to deliver HIV treatment and study the epidemiology of sexually
transmitted diseases in Santo Domingo, Dominican Republic.
Furuya EY,
Paez A, Srinivasan A, Cooksey R, Augunbraun M, Baron M, Brudney K,
Della-Latta P, Concepcion E, Fischer S, Flood M, Kellner P, Roman C,
Yakrus M, Weiss D, Granowitz EV. "Outbreak of Mycobacterium abscessus wound
infections among 'Lipotourists' from the United States who underwent
abdominoplasty in the Dominican Republic." Clinical Infectious Diseases
46:1181-8; 2008.
Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M, Addesso-Dodd
V, Shane E. Bone mass and mineral metabolism in HIV-infected
postmenopausal women. Osteoporos Int. 2005;16:1345-1352.
Wilkin TJ, Palmer S, Brudney KF, Chiasson MA, Wright TC. Anal
intraepithelial neoplasia in heterosexual and homosexual HIV-positive men
with access to anti-retroviral therapy. J Infect Dis. 2004;190:1685-1691.
Ellerbock TV et al. Incidence of cervical squamous intraepithelial
lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
Sackoff J et al. Purified protein derivative testing and tuberculosis
preventive therapy for HIV-infected patients in NYC. AIDS. 1998;12:2017-2023.
Frieden TR et al. A multi-institutional outbreak of highly drug-resistant
tuberculosis: Epidemiology and clinical outcomes. JAMA. 1996;276:1229-1235.
Brudney K. Homelessness and tuberculosis: A study in failure. J Law
Med Eth. 1993;23:360-367.
Brudney K, Dobkin JF. A tale of two cities: TB control in Nicaragua and
New York. Sem Resp Inf. 1991;6:261-272.
Brudney K, Dobkin JF. Resurgent tuberculosis in New York City: HIV
homelessness and the decline of TB control programs. Am Rev Respir
Dis. 1991;144:745-749.
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-7068
Fax: 212-305-7692
E-mail: firstname.lastname@example.com
Mary Ann Chiasson, MS, MPH, DrPH
Associate Professor of Clinical Epidemiology (in Medicine)
Bennington College, BA, 1972
New York University, MS, 1978
Columbia University Mailman School of Public Health, MPH, 1985
Columbia University Mailman School of Public Health, DrPH, 1988
SPECIALTY: Epidemiology
of HIV, HPV, and other STIs; reproductive health
Dr. Mary Ann Chiasson is an epidemiologist with a part-time faculty appointment in the Division of Infectious Diseases. Her primary appointment is in the Epidemiology Division at Columbia's Mailman School of Public Health where she has co-directed the Epidemiology of HIV/AIDS course since 1989. Dr. Chiasson has been the vice president for research and evaluation at Public Health Solutions since 1999. Before joining Public Health Solutions, she served for nine years as an assistant commissioner of health at the New York City Department of Health with scientific and administrative responsibility for AIDS surveillance, HIV/AIDS research and vital statistics, and epidemiology. Dr. Chiasson's research interests include the epidemiology of HIV (particularly risk factors for sexual transmission), women's reproductive health, and obesity. Her current research focuses on the relationship between the Internet and high risk sexual behavior among men who have sex with men and tailored interventions using digital media. The online HIV prevention videos produced by the research collaboration she leads can be viewed at http://www.hivbigdeal.org/.
Hirshfield S, Chiasson MA, Joseph H, Scheinmann R, Johnson WD, Remien RH, Shaw FS, Emmons R, Yu G, and Margolis AD. An Online Randomized Controlled Trial Evaluating HIV Prevention Digital Media Interventions for Men who have Sex with Men. PLoS One 2012, 7(10): e46252. doi:10.1371/journal.pone.0046252. Epub 2012 Oct 2.
Garbers S, Meserve A, Kottke M, Hatcher RA, Ventura A, Chiasson MA. Tailored health messaging improves contraceptive continuation and adherence: Results from a randomized controlled trial. Contraception. 2012 nov; 86(5):536-42. Doi: 10.1016/j; Mar 23 [Epub ahead of print]
Garbers S, Meserve A, Kottke M, Hatcher RA, Ventura A, Chiasson MA. Randomized controlled trial of a computer-based module to improve contraceptive method choice. Contraception. 2012 Oct; 86(4):383-90. Doi: 10. 1016/j.Mar 6 [Epub ahead of print]
Margolis AD, Joseph H, Belcher L, Hirshfield S, Chiasson MA. 'Never Testing for HIV' among Men who Have Sex with Men recruited from a sexual networking website, United States. AIDS and Behavior, 2012; 16: 23-9
Chiasson MA, Hirshfield S, Rietmeijer C. HIV Prevention and Care in the Digital Age. J Acquir Immune Defic Syndr 2010;55:S94-S97
Chiasson MA, Shuchat Shaw F, Humberstone M, Hirshfield S, Hartel D. Increased HIV disclosure three months after an online video intervention for men who have sex with men (MSM). AIDS Care 2009; 21:1081-1089.
Chiasson MA, Hirshfield S, Remien RH, Humberstone M, Wong T, Wolitski RJ. A comparison of online and offline sexual risk in men who have sex with men: An event-based online survey 2006. JAIDS 2007;44:235-243.
Aidala AA, Lee G, Garbers S, Chiasson MA. Sexual behavior and sexual risk in a prospective cohort of HIV-positive men and women in New York City, 1994-2002: Implications for prevention. AIDS Educ Prev 2006; 18:12-32.
Chiasson MA, Parsons JT, Tesoriero JM, Carballo-Dieguez A, Hirshfield S, Remien RH. HIV behavioral research online. J Urban Health 2006; 83:73-85.
Ellerbrock TV, Chiasson MA, Bush TJ, Sun X-W, Sawo D, Brudney K, Wright TC. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, Mojica BA Hamburg MA. Declining HIV/AIDS mortality in New York City. JAIDS.1999;21:59-64.
Sun X-W, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.
Health Solutions
220 Church Street, 5th floor
New York, NY 10013
Tel: 646-619-6411
Fax: 646-619-6777
NAME: Phyllis Della-Latta, PhD, MSc, D(ABMM)
Director, Clinical Microbiology Service
Professor of Clinical Pathology in Medicine
St. John's University, MSc,
New York University, PhD, 1978
Innovative laboratory diagnostic assays, molecular technology, rapid detection of hospital-associated and community-associated pathogens, multidrug resistant pathogens
Dr. Phyllis Della-Latta is Professor of Clinical Pathology in Medicine and Director of the Clinical Microbiology Service at the Columbia University Medical Center, NYPH. She is the recipient of the Distinguished Achievements in Clinical Microbiology Award given by the American Society for Microbiology, NYC branch and is a fellow of the American Academy of Microbiology. Her current activities include USA editor-in-chief of the Reviews in Medical Microbiology, editor of Journal of Infections in Developing Countries and reviewer of several national and international scientific journals. Dr. Della-Latta has served as Chair of the Advisory Committee to the Commissioner of Health on emerging pathogens and bioterrorism and serves as advisor to many organizations, including the Food and Drug Administration medical devices committee. Her appointments in professional societies include President and both fund-raising and program chair of the American Society of Microbiology, NYC branch. She was a former chair of the Microbiology Section of the New York Academy of Sciences and served on the NYAS presidential advisory council.
Schuetz, A.N., R.C. Huard, M.W. Eschoo, C. Massire, P. Della-Latta, F. Wu, S.G. Jenkins (2012) Identification of a novel Acinetobacter baumannii clone in a US hospital outbreak by multilocus polymerase chain reaction/electrospray-ionization mass spectrometry. Diag Micro Infect Dis. 72:14-19
Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L and Kubin CJ. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J. Clin Micro 49:1795-1798, 2011
Wu F, Della-Latta P, Tyagi S and Kramer FR. Detection of Pathogenic Organisms with Multicolor Molecular Beacons. In Molecular Microbiology. Diagnostic Principles and Practice, Chapter 15, 2nd edition, Ed. David H. Persing, ASM Press, Washington, DC, 2011
Morgan ME, Marlow E, Della-Latta P, Salimnia H, Novak-Weekley S, Wu F and Crystal BS. Multicenter evaluation of a new shortened peptide nuclei acid fluorescence in situ hybridization procedure for species identification of select gram-negative bacilli from blood cultures. J. Clin Microbiol 47:2269-2270, 2010.
Carey AJ, Della-Latta P, Huard R, Wu F, Graham PL, Carp D and Saiman L. Changes in the molecular epidemiology of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Infect Control Hosp Epidemiol 31:613-619, 2010.
Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ. Carbapenem-resistant Klebsiella pneumoniae bacteremia:factors correlated with clinical and microbiologic outcomes. Diag Micro Infect Dis 67:180-184, 2010
Mittman SA, Huard RC, Della-Latta P and Whittier S. Comparison of BD Phoenix to Vitek 2, MicroScan MICroSTREP and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol 47:3557-3561, 2010.
Lo A, Verrall R, Williams J, Stratton C, Della-Latta P and Tang YW. Carbapenem resistance via the blaKPC-2 gene in Enterobacter cloacae blood culture isolate recovered from a 34-month old boy in Tennessee. Southern Med J. 103:453-454, 2010
Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P and Huard RC. Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City Hospital. Antimicro. Agents Chemother. 53:1998-2004, 2009
Reich-Slotky R, Kabbash DA, Della-Latta P, Blanchard JS, Feinmark SJ, Freeman S, Kaplan G, Shuman HA and Silverstein SC. Gemfibrozil (Lopid) inhibits Legionella pneumophila and Mycobacterium tuberculosis enoyl-coenzyme A reductases and blocks intracellular growth of these bacteria in macrophages. J Bacteriol 191:5262-5271, 2009.
Della-Latta P, Gjeltena L, Jost K., Metchock B, Roberts GD, Salfinger M, Schwabb D, Tans-Kersten J, Tran A, Warshauer D, Woods G and Wroblewski K. Mycobacterium tuberculosis: Assessing Your Laboratory. Association of Public Health Laboratories (APHL), 2009.
Reich-Slotsky R., Wu F, Della-Latta P, Savage DG and Schwartz J. Application of pulsed-field electrophoresis to dienify the source of bacterial contamination of peripheral blood progenitor cell products. Transfusion 48:2409-2423, 2008.
Shepard JR, Addison RM, Alexander BD, Della-Latta P, Gherna M, Haase G, Hall G, Johnson JK, Merz WG, Peltroche-Llacsahuanga H, Stender H, Venezia RA, Wilson D, Procop GW, Wu F and Fiandaca MJ. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization methods for simultaneous dual-color identification of C.albicans and C.glabrata directly from blood culture bottles. J. Clin Micro 46:50-55, 2008.
Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, Brudney K, Della-Latta P, Estivariz C, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D and Granowitz E. Outbreak of Mycobacterium abscessus wound infections among "lipotourists" from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46:1181-1188, 2008.
Bodle ED, Cunningham JA, Della-Latta P, Schluger NW and Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emer Infect Dis 14:390-396, 2008.
Schlaberg R, Huard RC and Della-Latta P. Nocardia cyriacigeorgica, an emerging pathogen in the United States. J. Clin. Micro 46:265-273, 2008.
Della-Latta P. Nucleic Acid Amplification Tests (NAATs) for Direct Detection of M. tuberculosis Complex in Clinical Specimens; Approved Guideline, In Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS), Chapter 7.2, Volume 28, M48-A, Wayne, PA, 2008
Cook HA, Cimiotti JP, Della-Latta P, Saiman L and Larson EL. Antimicrobial resistance patterns of colonizing flora on nurses' hands in the neonatal intensive care unit. Amer J. Infect Control 35:231-236, 2007.
Chen KT, Campbell H, Borrell LN, Huard RC, Saiman L and Della-Latta P Predictors and outcomes for pregnanat women with vaginal-rectal carriage of community-associated methicillin-resistant Staphylococcus aureus. Am J. Perinatol 24:235-240, 2007
Alberte-Castineiras, A, Brezmes-Valivieso MG, Campos-Bueno A, Montes-Martinez I, Lopez-Medrano R, Avellaneda C, Perez-Pascual P and Della-Latta P. Drug-resistant tuberculosis in Castilla-Leon, Spain, 1996-2000. Int J Tuberc Lung Dis 10:554-558, 2006.
Wu F and Della-Latta P. Pulsed- Field Gel Electrophoresis (PFGE). In Advanced Techniques in Diagnostic Microbiology, Part I, Chapter 9, pp. 143-157. Eds.Yi-Wei Tang and C.W. Stratton. Springer Science & Business Media, LLC, 2006.
Department of Pathology
Clinical Microbiology Service, CHC 3-325
622 West 168th Street
New York, NY 10032
Tel: (212) 305-2929
Fax: (212) 305-8971
E-mail: email@example.com
Jay Dobkin, MD
Arnold P. Gold Foundation Associate Professor of Clinical Medicine
Columbia College, BA, 1968
Dartmouth Medical School, BMS, 1970
Harvard Medical School, MD, 1972
SPECIALTY: Antiretroviral therapy, harm reduction
Dr. Jay Dobkin is the Arnold P. Gold Foundation Associate Professor of
Clinical Medicine. Dr. Dobkin is the director of the AIDS program at
Columbia University Medical Center. He is the principal investigator of
an ongoing series of quantitative assessments of interventions to promote
improved adherence to antiretroviral therapy. Dr. Dobkin is also
developing assessment strategies for antiretroviral treatment programs
targeting injection drug users in the former Soviet Union in
collaboration with several nongovernmental organizations active in these
areas including the Open Society Institute (New York) and the Open Health
Institute (Moscow). He serves as a consultant to the World Health
Organization on care and treatment of HIV-infected injection drug users.
He is involved in research examining the pathogenesis of HIV-associated
bone loss in a longitudinal cohort of postmenopausal women. Dr. Dobkin is
also the principal investigator of several industry-sponsored studies of
new antiretroviral agents.
Dobkin J. Preventing pneumococcal disease. AIDS Reader. 2006.
16(2):81-2 AIDS Read. 2006 Feb;16(2):81-2.
Yin M, Dobkin JF, Brudney KF, Becker C, Zadel JL, Manandhar M,
Addesso-Dodd V, Shane E. Bone mass and mineral metabolism in HIV-infected
postmenopausal women. Osteoporos Int. 2005;16:1345-1352.
Bangsberg D et al. Reduction in tuberculin skin-test conversions among
medical house staff associated with improved tuberculosis infection
control practices. Infect Control Hosp Epidemiol. 1998;18:566-570.
Simpson D et al. Peptide T in the treatment of painful distal neuropathy
associated with AIDS: Results of a placebo-controlled trial. Neurology. 1996;44:1254-1259.
Lutfey M et al. Independent origin of mono-rifampin-resistant
mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit
Care Med. 1996;153:837-840.
Thomas C, Dobkin JF, Weinberger O. TAT-medicated transcellular activation
of HIV-1 long terminal repeat directed gene expression by HIV-1 infected
peripheral blood mononuclear cells. J Immunology. 1994;153:3831-3839.
Gormam JM et al. Development and characteristics of a medical staging
system for HIV infection. Int J Methods Psychiatr Res. 1993;2:117-124.
Brunswick A et al. HIV-1 seroprevalence and risk behaviors in an urban
African American community cohort. Am J Public Health. 1993;83:1390-1394.
Cohn D, Dobkin JF. Treatment and prevention of tuberculosis in HIV
infection. AIDS. 1993;7(suppl 1):S195-S202.
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-8507
Fax: 212-305-7692
E-mail: email@example.com
NAME:Tanya Ellman, MD, MS
Instructor in Clinical Medicine
Wesleyan University, BA, 2001
Weill Medical College of Cornell University, MD, 2007
SPECIALTY: HIV epidemiology, prevention, and clinical care, International HIV
Dr. Ellman is an instructor in Clinical Medicine in the Division of Infectious Diseases. She also holds the position of Associate Research Scientist at ICAP, which, based in the Mailman School of Public Health, provides implementation and technical assistance for HIV and related health programs across Africa and Central Asia. In her role there as Adult HIV Care and Treatment Clinical Officer, she provides technical guidance to in-country staff, designs and implements training programs, and conducts clinical and epidemiological research in HIV, tuberculosis and related disorders. Dr. Ellman's primary research interests include late HIV diagnosis and delayed entry to care, particularly in older adults, aggregate HIV viral load measurements as a tool for monitoring HIV epidemics, and representation of Latinos and African Americans in preventive HIV vaccine trials.
Justman J, Ellman T, Donnell D, Duong Y, Reed J, Bicego G, Ehrenkranz P, Wang L, Bock N, Nkambule R. Population HIV viral load estimate in Swaziland: assessing ART program effectiveness and transmission potential. Abstract #96, 20th Conference on Retroviruses and Opportunistic Infections, 2013
Kapur A, Tang EC, Van Tieu H, Koblin BA, Ellman TM, Sobieszczyk ME. Knowledge, attitudes, and willingness of New York City (NYC) providers to prescribe oral pre-exposure prophylaxis (PrEP) for HIV prevention. Abstract WEPE273, XIX International AIDS Conference, 2012
Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MY. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect (2012); 65: 80-87.
Ellman TM, Dickey LJ, Phadke VK, Calfee DP, Yin MT, Kubin CJ. Incidence and predictors of acute kidney injury (AKI) associated with intravenous (IV) polymyxin B (PB) therapy. Abstract K-962, 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2011
Ellman T, Enschede E, Fein O. HIV/AIDS care and prevention in the Cuban health system. International Health and Medical Education Consortium Annual Conference, 2005
Columbia University Medical Center
630 West 168th Street
P&S Box 82
New York, NY 10032
Tel: (212) 342-3767
Fax: (212) 342-1824
E-mail: email@example.com
NAME: David A. Fidock, PhD
Professor of Microbiology & Immunology and of Medical Sciences in Medicine
Adelaide University, South Australia B.Sc., 1986
University Paris VII, France, Ph.D.,
Malaria drug resistance, chemotherapy, pathogenesis, fatty acid metabolism, cell development
Biological investigations into Plasmodium falciparum, the etiologic agent of severe malaria, reveal an organism that is tremendously adept at overcoming therapeutic attack and evading host immunity. This haploid apicomplexan parasite causes disease in over 220 million individuals and kills over 600,000 African children yearly, and prevents sterilizing immunity from being acquired even by individuals who have been infected thousands of times. Disease can result from severe anemia, hyperparasitemia, or other complications resulting from sequestration of parasitized red blood cells (RBC) in the microvasculature, a process that depends on the presentation of antigenically distinct parasite proteins on the infected RBC surface. Chemotherapeutic clearance of asexual blood stage parasites is the linchpin of malaria treatment and control, however it is systematically thwarted by the acquisition of resistance. The most dramatic consequence has been with chloroquine (CQ), for decades the gold standard until resistance appeared and pre-empted a dramatic increase in malaria mortality and morbidity rates, particularly in Africa.
During my past 24 years of malaria research, I have studied how P. falciparum invades and develops within hepatocytes and RBC, what immune effector mechanisms operate on these stages, how antimalarials act and how parasites counter their action, and how parasites are successfully transmitted to Anopheles mosquitoes, their definitive host. My laboratory's ongoing and planned research channels these interests into several themes: 1) What are the parasite factors that mediate resistance to antimalarial drugs; 2) What biological processes are targeted by antimalarial drugs and what accounts for parasite death; 3) What biochemical and physiological functions are intrinsic to the digestive vacuole and the apicoplast, the site of action of CQ and of antibiotics respectively; and 4) How does P. falciparum regulate its virulence and prevent the establishment of protective immunity. These studies benefit from our extensive experience in P. falciparum transfection and we constantly strive for new innovations in genetics to enhance the power of these investigations.
Johnston GL, Smith DL and Fidock DA (2013). Malaria's missing number: calculating the human component of R0 by a within-host mechanistic model of Plasmodium falciparum infection and transmission (2013). PLoS Comp. Biol. (in press).
Falkard B, Kumar TR, Hecht LS, Matthews KA, Henrich PP, Gulati S, Lewis RE, Manary MJ, Winzeler EA, Sinnis P, Prigge ST, Heussler V, Deschermeier C and Fidock DA (2013). A key role for lipoic acid synthesis during Plasmodium liver stage development. Cell. Microbiol. (in press).
McMillan PJ, Millet C, Batinovic S, Maiorca M, Hanssen E, Kenny S, Muhle RA, Melcher M, Fidock DA, Smith JD, Dixon MW and Tilley L (2013). Spatial and temporal mapping of the PfEMP1 export pathway in Plasmodium falciparum. Cell. Microbiol.(in press).
Bopp SE, Manary MJ, Bright AT, Johnston GL, Dharia NV, Luna FL, McCormack S, Plouffe D, McNamara CW, Walker JR, Fidock DA, Denchi EL and Winzeler EA (2013). Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet. 9: e1003293.
Ecker A, Lehane AM, Clain J and Fidock DA (2012). PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 28: 504-14.
Straimer J, Lee MC, Lee AH, Zeitler B, Williams AE, Pearl JR, Zhang L, Rebar EJ, Gregory PD, Llinas M, Urnov FD and Fidock DA (2012). Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nature Methods 9: 993-8.
Crabb BS, Beeson JG, Amino R, Menard R, Waters A, Winzeler EA, Wahlgren M, Fidock DA and Nwaka S (2012). Malaria Perspectives: The missing pieces. Nature 484: S22-3.
Uhlemann AC and Fidock DA (2012). Loss of malarial susceptibility to artemisinin in Thailand. The Lancet 379: 1928-30.
Meister S, Plouffe DM, Kuhen K, Bonamy GMC, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Gagaring K, Gettayacamin M, Groessl t, Kato N, Lee MCS, McNamara CW, Fidock DA, Nagle A, Nam T-G, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Diagana TT, Chatterjee A and Winzeler EA (2011). Exploring malaria hepatic stages to find next generation antimalarial drugs. Science 334: 1372-7.
Adjalley SH, Johnston G, Li T, Eappen AG, Eastman RT, Ekland EH, Richman A, Sim BKL, Lee MCS, Hoffman SL and Fidock DA (2011). Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity of the synthetic dye methylene blue. Proc. Natl. Acad. Sci. USA 108: E1214-23.
O'Brien C, Henrich PP, Passi N and Fidock DA (2011). Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 24: 570-7.
Yuan J, Cheng KC, Johnson RL, Huang R, Pattaradilokrat S, Liu A, RajarshiGuha, Fidock DA, Inglese J, Wellems TE, Austin CP and Su X (2011). Chemical genomic profiling for antimalarial therapies, response signatures and molecular targets. Science 333: 724-9.
Ekland EH, Schneider J and Fidock DA (2011). Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches. The FASEB J. 25: 3583-93.
Ecker A, Lakshmanan V, Sinnis P, Coppens I and Fidock DA (2011). Evidence that mutant PfCRT facilitates the transmission to mosquitoes of chloroquine-treated Plasmodium gametocytes. J. Infect. Dis.203: 228-36.
Baschong W, Wittlin S, Inglis KA, Fairlamb AH, Croft SL, Kumar S, Fidock DA and Brun R (2011). Triclosan is minimally effective in rodent malaria models. Nature Med.17: 33-4.
Rottmann M, McNamara C, Yeung BKS, Lee MCS, Zou B, Russell B, Seitz P, Dharia NV, Plouffe DM, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck H-P, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA and Diagana TT (2010). Spiroindolones, a new and potent chemotype for the treatment of malaria. Science 329: 1175-80
Valderramos SG, Scanfeld D, Uhlemann A-C, Fidock DA* and Krishna S* (2010). Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob. Agents Chemother. 54: 3842-52. *Co-corresponding.
Valderramos, SG, Valderramos JC, Musset L, Purcell LA, Mercereau-Puijalon O, Legrand E and Fidock DA (2010). Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog. 6: e1000887.
Fidock DA (2010). Drug discovery: Priming the antimalarial pipeline. Nature 465: 297-8.
Melcher M, Muhle RA, Henrich P, Kraemer SM, Avril M, Vigan-Womas I, Mercereau-Puijalon O, Smith JD and Fidock DA (2010). Identification of a role for the PfEMP1 semi-conserved head structure in protein trafficking to the surface of Plasmodium falciparum infected red blood cells. Cell. Microbiol. 12: 1446-1462.
Eastman RE and Fidock DA (2009). Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nature Rev. Microbiol. 7: 864-74.
Yuan J, Johnson RL, Huang R, Wichterman J, Jiang H, Hayton K, Fidock DA, Wellems TE, Inglese J,Austin CP and Su X-z (2009). Screening and genetic mapping targets of differential chemical-response phenotypes in Plasmodium falciparum. Nature Chem. Biol. 5: 765-71.
Dharia NV, Sidhu ABS, Cassera MC, Westenberger S, Bopp S, Eastman RT, Plouffe D, Batalov S, Park DJ, Volkman SK, Wirth DW, Zhou Y, Fidock DA and Winzeler EA (2009). Use of high-density tiling microarrays to globally identify mutations and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10: R21.
Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ, Moura PA, Lakshmanan V, Freundlich JS, VAlderramos JC, Vicheze C, Siedner M, Tsai JH, Flkard B, Sidhu AB, Purcell LA, Gratraud P, Kremer L, Waters AP, Schiehser, G, Jacobus DP, Janse CJ, Ager A, Jacobs WR Jr, Sacchettini JC, Heussler V, Sinnis P and Fidock DA (2008). The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host & Microbe 4: 567-78.
Fidock DA, Eastman RE, Ward SA and Meshnick SR (2008). Recent highlights in antimalarial drug resistance and chemotherapy research. Trends in Parasitol. 24: 537-44.
Lee MCS, Moura PA, Miller EA and Fidock DA (2008). Plasmodium falciparum Sec24 marks transitional ER that exports a model cargo via a diacidic motif. Mol. Microbiol. 68: 1535-1546.
Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Collins FH and Duffy PE (2008). Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118: 1266-1276.
Lee MCS and Fidock DA (2008). Arresting malaria parasite egress from infected red blood cells. Nature Chem. Biol. 4: 161-162.
Ekland EH and Fidock DA (2007). Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opinion Microbiol. 10: 363-370.
Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC and Fidock DA (2007). In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282: 2494-504.
Nkrumah LN, Muhle RA, Moura PA, Ghosh P, Hatfull G, Jacobs Jr. WR & Fidock DA (2006). Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nature Methods 3: 615-21.
Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, Muhle RA, Alakpa GE, Hughes RH, Ward SA, Krogstad DJ, Sidhu ABS and Fidock DA (2005). A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24: 2294-305.
Johnson DJ, Fidock DA*, Mungthin M, Lakshmanan V, Sidhu ABS, Bray PG and Ward SA* (2004) Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol. Cell 15: 867-77. *Co-corresponding authors.
Fidock DA, Rosenthal PJ, Croft SL, Brun R and Nwaka S (2004). Antimalarial drug discovery: efficacy models for compound screening. Nature Rev. Drug Disc. 3: 509-20.
Sidhu ABS, Verdier-Pinard D and Fidock DA (2002). pfcrt mutations confer chloroquine resistance to Plasmodium falciparum malaria parasites. Science 298: 210-3
Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su X-z, Nomura T, Fidock DA, Wellems TE and Plowe CV (2001). A molecular marker for chloroquine resistant falciparum malaria. New Engl. J. Med. 344:257-63.
Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu ABS, Deitsch K, Su X-z, Wootton JC, Roepe PD and Wellems TE (2000). Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:681-71.
Department of Medicine and Microbiology
Hammer Health Sciences Center Room 1502
701 West 168th Street
New York, NY 10032
Tel: (212) 305-0816
Fax: (212) 305-4038
Back to Top
NAME: Mary T. Flood, MD, PhD
Associate Clinical Professor of Medicine
Dominican College of Blauvelt, BS, 1968
New York University, PhD, 1976
Teachers College, Columbia University, MA, 1983
Columbia College of Physicians and Surgeons, MD, 1987
SPECIALTY: General infectious diseases, HIV primary care, travel
With a background in cell biology and basic science research, Dr. Flood
focuses on clinical infectious diseases. Her interests include general
infectious diseases with a particular interest in HIV primary care,
infections in immunocompromised patients, endocarditis and septic
arthritis. Dr. Flood is also qualified to do travel recommendations and
Furuya, EY, Paez A, Srinivasin A, et al "Outbreak of Mycobacterium abscesses wound infections among "liptourists" from the United States who underwent abdominoplasty in the Domincan Republic". Clin Inf Dis 46(2008):1181-1188.
Flood MT. "Infectious Arthritis." In: Current Practice of
Medicine. RC Bone MD ed. Current Medicine, Philadelphia 1996, VIII:
Brunswick AF, Messeri PA, Dobkin J, Flood MT, Yang A. "Sibling
homophily in HIV infection: biopsychosocial linkages in an urban
African-American sample. NIDA Research Monograph 151, 1995
Blaner WS, Das Sr, Gouras P, Flood MT. "Hydrolysis of 11-cis and
all-trans retinyl palmitate by homogenates of human retinal epithelial
cells. J Biol Chem 262 (1987): 53-58.
Flood MT, Gouras P, Kjeldbye H. "Growth characteristics and
ultrastructure of human retinal pigment epithelium in vitro. Invest
Ophthal Vis Sci 19 (1980): 1309-1320.
NewYork–Presbyterian Hospital
161 Fort Washington Avenue
Irving Pavilion, Room 215
New York, NY 10032
Tel: 212-305-8039
Fax: 212-305-1754
E-mail: firstname.lastname@example.com
Back to Top
E. Yoko Furuya, MD, MS
Assistant Professor of Clinical Medicine
Harvard University, BA, 1995
University of Pennsylvania School of Medicine, MD, 1999
Columbia University Mailman
School of Public Health, MS (Epidemiology), 2006
SPECIALTY: Clinical research in hospital epidemiology and
antimicrobial resistance
Dr. E. Yoko Furuya is the Medical Director of Infection Control and Hospital Epidemiology for NewYork-Presbyterian Hospital. She is also the Director of Antimicrobial Stewardship for NewYork-Presbyterian Hospital. Her research interests are focused in the areas of hospital epidemiology and antimicrobial resistance. She is a co-investigator on numerous NIH- and CDC-funded grants on topics such as multidrug-resistant gram-negative bacilli, the financial costs of healthcare-associated infections and antimicrobial resistance, and the impact of an automated infection control surveillance system on isolation precautions for/transmission of methicillin-resistant Staphylococcus aureus (MRSA). She is also currently working on the evaluation of antimicrobial stewardship interventions on antimicrobial utilization and resistance patterns, as well as the evaluation of a hand hygiene compliance program on the transmission of multidrug-resistant organisms.
Bhadelia N, Sonti R, Wright-McCarthy J, Vorenkamp J, Jia H, Saiman L, Furuya EY: Impact of the 2009 influenza A (H1N1) pandemic on healthcare workers at a tertiary care center in New York City. Infect Control Hosp Epidemiol [in press]
Cohen B, Choi YJ, Hyman S, Furuya EY, Neidell M, Larson E: Gender differences in risk of bloodstream and surgical site infections. J Gen Intern Med [epub ahead of print]
Zhou JJ, Patel SJ, Jia H, Weisenberg SA, Furuya EY, Kubin CJ, Alba L, Rhee K, Saiman L: Clinicians' Knowledge, Attitudes, and Practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units. Infect Control Hosp Epidemiol 34: 274-83, 2013.
Pogozelska-Maziarz M, Furuya EY, Larson EL: Risk factors for methicillin-resistant Staphylococcus aureus bacteraemia differ depending on the control group chosen. Epidemiol Infect 21: 1-8, 2013.
Jeon CY, Furuya EY, Berman MF, Larson EL: The role of pre-operative and post-operative glucose control in surgical-site infections and mortality. PLoS One 7(9): e45616, 2012.
Kubin CJ, Jia H, Alba LR, Furuya EY: Lack of significant variability among different methods for calculating antimicrobial days of therapy. Infect Control Hosp Epidemiol 33 (Special Topic Issue: Antimicrobial Stewardship): 421-3, 2012.
Bright TJ, Furuya EY, Kuperman GJ, Cimino JJ, Bakken S: Development and evaluation of an ontology for guiding appropriate antibiotic prescribing. J Biomed Inform 45: 120-8, 2012.
Apte M, Neidell M, Furuya EY, Caplan D, Glied S, Larson E: Using electronically available inpatient hospital data for research. Clin Trans Sci 4: 338-45, 2011.
Pogorzelska M, Stone PW, Furuya EY, Perencevich EN, Goldmann D, Dick A: Impact of the ventilator bundle on ventilator associated pneumonia in intensive care units. Int J Qual Health Care 23: 538-44, 2011.
Furuya EY, Larson E, Landers T, Jia H, Ross B, Behta M: Challenges of applying the SHEA/HICPAC metrics for multidrug-resistant organisms to a real-world setting. Infect Control Hosp Epidemiol 32: 323-32, 2011.
Furuya EY, Dick A, Perencevich EN, Pogorzelska M, Goldmann D, Stone PW: Central line bundle implementation in US intensive care units and impact on bloodstream infections. PLoS One 6:e15452, 2011.
Furuya EY, Dick A, Perencevich EN, Pogorzelska M, Goldmann D, Stone PW: Central Line Bundle Implementation and Impact on Infection Rates in US Intensive Care Units (ICU). Oral Presentation, "The Cutting Edge of Infection Prevention: The Top Four Submitted Papers of the 2010 Decennial." Abstract #2289. Fifth Decennial International Conference on Healthcare-Associated Infections, March 2010. Atlanta, GA.
Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ: Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 67: 180-4, 2010.
Furuya EY, Kubin CJ: Antibiotic prophylaxis. In: Cohen, Powderly, and Opal, eds. Infectious Diseases, 3rd ed. Oxford: Mosby Elsevier; 2010. pp. 1323-1332.
Miller M, Cook HA, Furuya EY, Bhat M, Lee MH, Vavagiakis P, Visintainer P, Vasquez G, Larson E, Lowy FD: Staphylococcus aureus in the community: colonization versus infection. PLoS One: 4: e6708, 2009.
Stone PW, Dick A, Pogorzelska M, Horan TC, Furuya EY, Larson E: Staffing and structure of infection prevention and control programs. Am J Infect Control 37: 351-7, 2009.
Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, Brudney K, Della-Latta P, Estivariz C, Fischer S, Flood M, Kellner P, Roman C, Yakrus M, Weiss D, Granowitz EV: Outbreak of Mycobacterium abscessus wound infections in US lipotourists who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46: 1181-8, 2008.
Furuya EY, Cook HA, Lee M, Miller M, Larson E, Hyman S, Della-Latta P, Mendonca E, Lowy FD: Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it? A methodological comparison of prevalence ascertainment. Am J Infect Control 35: 359-66, 2007.
Cook H, Furuya EY, Larson E, Vasquez G, Lowy FD: Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 44: 410-3, 2007.
Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nature Rev Microbiol 4: 36-45, 2006.
Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ: Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemotherapy 54: 566-9, 2004.
Furuya EY, Lowy FD: Antimicrobial strategies for the prevention and treatment of cardiovascular infections including cardiothoracic surgery and device implants. Curr Opin Pharmacol 3: 464-9, 2003.
of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: email@example.com
NAME: Peter Gordon,
Assistant Professor of Clinical Medicine
SUNY at Stony Brook, BS, 1986
SUNY at Stony Brook, School of Medicine, MD, 1990
SPECIALTY: HIV primary care, HIV/HCV co-infection, HIV clinical trials.
Dr. Gordon is the Medical Director of the Comprehensive HIV Program at New York Presbyterian Hospital. His clinical work includes practicing as an HIV Specialist and Primary Care Provider within the Designated AIDS Center at the Columbia University Medical Center and as a clinical investigator within the Columbia Collaborative HIV/AIDS Clinical Trials Unit. Dr. Gordon serves as Chair of the New York State AIDS Institute Quality of Care Advisory Committee, as a member of the AIDS Institute's Medical Care Criteria Committee, and on the Clinical Committee of Healthix, a regional health information exchange (RHIO) based in NYC.
Dr. Gordon is a co-investigator for the Adult AIDS Clinical Trials Unit at CUMC and a co-investigator for industry-sponsored studies of new antiretroviral agents. He is the principle investigator for a number of HRSA Special Projects of National Significance (SPNS) that focus upon the use of Health Information Technology (HIT) to improve clinical care and care coordination. Additional areas of interest include the use of innovative HIT models for HIV and STI prevention and care engagement, the impact of chronic HIV on co-morbidities, and HIV health care policy.
Odlum M, Gordon P, Camhi E, Schnall R, Teixeira P, Bakken S. Perceptions of Predisposing, Enabling, and Reinforcing Factors for Use of a Continuity of Care Document for People Living with HIV/AIDS, Journal of Healthcare for Poor and Underserved. 2012;23(4):1457-76
Gordon, P, Camhi E, Odlum M, Schnall R, Rodriguez M, Valdez E, Bakken S. Processes and Outcomes of Developing a Continuity of Care Document for Use as a Personal Health Record by People Living with HIV/AIDS in New York City. International Journal of Medical Informatics. 2012; 81(10): e63-73
Schnall R, Smith AB, Sikka M, Gordon P, Camhi E, Kanter T, Bakken S. Employing the FITT framework to explore HIV case managers' perceptions of two electronic clinical data (ECD) summary systems. International Journal of Medical Informatics. 2012; 81(10): e56-72
Schnall R, Smith, SB, Gordon P, Camhi E, Sikka M, Kanter T, Bakken S. Barriers and Facilitators of Implementing Personal Health Records in HIV/AIDS Care. Studies in Health Technology and Informatics, 2012
Schnall R, Gordon P, Camhi E, Bakken S. Perceptions of Factors Influencing Use of an Electronic Record for Case Management of Persons Living with HIV. AIDS Care. 2011 Mar;23(3):357-65
Teixeira PA, Gordon P, Canhi E, Bakken S. HIV Patients' Willingness to Share Personal Health Information Electronically. Patient Education and Counseling. 2011 Aug: 84(2):e9-12
Schnall R, Odlum M, Gordon P, Bakken S. Barriers to implementation of a Continuity of Care Record (CCR) in HIV/ AIDS care. Studies in Health Technology and Informatics 2009;146:248-52
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-3272
Fax: 212-305-7692
E-mail: firstname.lastname@example.com
NAME: Rachel J.
Gordon, MD, MPH
Assistant Professor of Clinical Medicine
Assistant Professor of Clinical Epidemiology
Yale University, B.S., 1996
Vanderbilt University School of Medicine, M.D., 2000
Columbia University Mailman School of Public Health, M.P.H. 2004
SPECIALTY: Staphylococcal molecular epidemiology and pathogenesis
Dr. Rachel Gordon is an Assistant Professor in Clinical Medicine in the Division of Infectious Diseases at the Columbia University Medical Center and in epidemiology at the Mailman School of Public Health. Her research interests include the molecular epidemiology of Staphylococcal colonization and disease in high-risk populations as well as Staphylococcal pathogenesis. Dr. Gordon has been investigating ventricular assist device-related infections (VADs) and the molecular epidemiology of Staphylococcus epidermidis, which is frequently involved with these infections. She is also interested in bacterial infections in drug users. Dr. Gordon is also an active educator, the recipient of several teaching awards and is a member of the Virginia Apgar Academy of Medical Educators. She is the section director for Microbiology/Infectious Diseases at Physcians & Surgeons and teaches "Biology and Pathophysiology for Epidemiologist" in the Epidemiology doctoral program at the Mailman School of Public Health. She enjoys working with and training clinical fellows and residents.
Gordon, R. J., A. D. Weinberg, F. D. Pagani, M. S. Slaughter, P. S. Pappas, Y. Naka, D. J. Goldstein, W. P. Dembitsky, J. C. Giacalone, J. Ferrante, D. D. Ascheim, A. J. Moskowitz, E. A. Rose, A. C. Gelijns, and F. D. Lowy. 2013. Prospective, multicenter study of ventricular assist device infections. Circulation 127:691-702. PubMed # 23315371 NIHMSID # 440295
Gordon, Rachel J., Maria Miragaia, Alan D. Weinberg, Caroline J Lee, Joana Rolo, Julie C. Giacolone, Mark S. Slaughter, Pat Pappas, Yoshifumi Naka, Alfred J. Tector, Herminia de Lencastre, Franklin D. Lowy. Staphylococcus epidermidis colonization is highly clonal across United States cardiac centers. Journal of Infectious Diseases. 2012 May 1;205(9):1391-8.
Gordon, Rachel J., N. Chez, H. Jia, B. Zeller, M. Sobieszczyk, C. Brennan, K. Hisert, Mei-Ho Lee, P. Vavagiakis, and Franklin D. Lowy. The NOSE Study (Nasal Ointment for Staphylococcus aureus Eradication): A Randomized Controlled Trial of Monthly Mupirocin in HIV-Infected Individuals. J of Acquired Immune Deficiency Syndromes. 2010 Sept;55(2).
Schulman AR, Martens TP, Russo MJ, Christos PJ, Gordon RJ, Lowy FD, Oz MC, Naka Y. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant. 2009 Mar;28(3):237-42.
Gordon, R.J. and F.D. Lowy. Pathogenesis of Methicillin-Resistant Staphylococcus aureus Infection. Clinical Infectious Diseases 2008; 46:S350-9.
Gordon, R.J., B. Quagliarello, and F.D. Lowy. Ventricular assist device-related infections. Lancet Infect. Dis. 2006; 6:426-37.
Gordon, R.J. and F.D. Lowy. Bacterial Infections in Drug Users. NEJM 2005; 353:1945-54.
Gordon, R.J., B. Quagliarello, C. Cespedes, M. Chung, H. de Lencastre, P. Vavagiakis, M. Miller, B. Zeller, and F.D. Lowy. A Molecular Epidemiological Analysis of 2 Staphylococcus aureus Clonal Types Colonizing and Infecting Patients with AIDS. Clin. Infect. Dis. 2005;40:1028-1036.
Cespedes, C., B. Said-Salim, M. Miller, S.H. Lo, B.N. Kreiswirth, R.J. Gordon , P. Vavagiakis, R.S. Klein, and F.D. Lowy FD. The clonality of Staphylococcus aureus nasal carriage. J. Infect. Dis. 2005;191(3):444-52.
Rachel J. Gordon, MD, MPH, William J. Pluta, Boyd F. Richards, PhD. Innovative Strategies for Active Learning within a "Flipped" Classroom Environment: Team-based Learning and Just-In-Time Teaching Compared. Presentation Proposal submitted to the Association of American Medical Colleges' NEGEA Educational Retreat Spring Meeting April 2013, New York, NY.
N. A. Weitz, F. N. White, R. J. Gordon, K. D. Morel, M. C. Garzon, P. J. Planet, C. T. Lauren. Staphylococcus aureus Colonization in Children with Atopic Dermatitis. Summer Academy Meeting of the American Academy of Dermatology, Boston, MA August 2012.
R. Gordon, A. Weinberg, F. Pagani, F. Lowy, and the VAD Infection Study Group. Prospective, multicenter investigation of ventricular assist device infections. Late-breaker, 50th Annual ICAAC Meeting, Boston, September 2010.
R. Gordon, M. Perlo, E. Hall. Innovative Teaching Methods: The Challenge of Effectively Training Faculty. Poster presentation at the NEGEA Annual Retreat at the University of Connecticut School of Medicine in Farmington, CT, March 2010.
Uhlemann-AC, Huard-R, Whittier-S, Della-Latta-P, Lowy-FD, Gordon-RJ. Clinical Vancomycin-Intermediate S. aureus (VISA) infection with a USA 300 strain. 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC., October 2008.
R. Gordon, N. Chez, H. Jia, B. Zeller, M. Sobieszczyk, C. Brennan, K. Hisert, M. Lee, P. Vavagiakis, F. Lowy. Monthly mupirocin decreases S. aureus nasal colonization in HIV/AIDS patients. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.
R. Gordon, M. Bhat, C. Fairchild, J. Choe, U. Rawiel, D. Ascheim, M. Slaughter, Y. Naka, F. Lowy. Ventricular Assist Device Recipients Share Commensal S. epidermidis Clones and are Infected with Colonizing Strains. Poster presentation at the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 2008.
Gordon, R. J., T. Martens, R. Wang, Y. Naka, B. Scully, E. Blumberg, and F. Lowy. Diagnostic Criteria for Diagnosing Ventricular Assist Device-Related Infections. Poster presentation at the 46th ICAAC, September, 2006.
Jankolovits, R., B. Quagliarello, C. Cespedes, M. Miller, M. Chung, H. De Lencastre, B. Zeller, J. Justman, and F.D. Lowy. Two clonal types of Staphylococcus aureus dominate infection and nasal colonization in a NYC AIDS and drug treatment facility. Slide presentation at the Interscience Conference on Antimicrobial Agents andChemotherapy (ICAAC), September, 2002.
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Phone: (212) 342-0109
Fax (212) 305-5794
NAME: Sandra Hyman,
Associate in Medicine
Molloy College, BS, 1981
New York University, MPA, 1986
SPECIALTY: Infection Prevention and Control
Sandra R. Hyman, RN, MPA, CIC , has been an Infection Prevention Specialist at NewYork-Presbyterian Hospital (NYPH) for over 8 years, and is an Associate in Medicine at the Columbia University, Department of Medicine, Division of Infectious Diseases. For the last 4 years at (NYPH) she has been providing education and infection prevention support for the adult and children's Perioperative Services. She is part of the Perioperative Services Leadership. In addition, Sandra Hyman has been a member of a research team at the Columbia University Center for Interdisciplinary Research to Reduce Antimicrobial Resistance. The team had a NIH Grant to study the economics of hospital infections.
Prior to NYPH she was an Infection Control Coordinator at Greenwich Hospital, in Greenwich, Connecticut (CT) for 15 years. She specialized in community acute care, home care and private office consulting. Sandra also managed some Employee Health functions. Sandra has been a member of The Association for Professionals in Infection Control and Epidemiology (APIC) for over 25 years, and served as Vice Chairman for the CT APIC Conference. She is currently a member of the APIC National Education Committee and the Education Committee liaison for the APIC Professional Development Committee.
Sandra is on the Advisory Board for the American Journal of Infection Control (AJIC) and has reviewed articles AJIC and the Joint Commission Journal on Quality and Patient Safety.
Frequency, Level, and Duration of Patient Contacts, And Observational Study and Survey of Physicians, Nurses, Clinical Staff and Visitors, The Joint Commission Journal of Quality and Patient Safety
S. Hyman, RN, MPA, CIC, L. Kertesz, ANP, MSN, CNOR, P. Nelson, RN, MSN,P. Nelson, RN, MSN, CNOR, A. Compton, MD, MPH, V. Almarez-Fox, RN, MPA, J. Evanko, MD, MBA, Engaging Staff to be Responsible for Surgical Site Infection Prevention in a Large Academic Tiertiary Hospital, Association for Professionals in Infection Control and Epidemiology, San Antonio, Texas.
Cohen B, Choi YJ, Hyman, SR, Furuya, EY, Neidell M, Larson, EL, Gender Differences in Risk of Bloodstream Infection, Association for Professionals in Infection Control and Epidemiology, San Antonio, Texas
S. Hyman, RN, MPA, CIC, K. Gasiorowski, RN, MSN, CNOR, L.Kertesz, ANP, MSN, CNOR, L. Posner, RN, BSN, M. O'Brien, RN, MA, CNOR SCIP-ing to the Next Level: Surgical Site Infection Prevention, Association of periOperative Registered Nurses, New Orleans, Louisiana.
M. Apte,MS, T. Landers, RN, Ph.D, E. Furuya, MD, MS, S. Hyman, RN, MPA,E. Larson, RN, PhD, A Comparison of Two Computer Algorithms to Identify Surgical Site Infections, Journal of Surgical Infections 2011 Dec;12(6):459-64.
S. Hyman, RN, MPA, CIC, B. Cohen, MPH, L. Rosenberg, BS, E. Larson, RN, Ph.D, Frequency, Level, and Duration of Patient Contacts, And Observational Study and Survey of Physicians, Nurses, Clinical Staff and Visitors, Association for Infection Prevention, Baltimore, Maryland, New York Academy of Medicine, Nursing Research Seminar
T. Landers, CNP, Ph.D, M. Apte, MBBS, MsPH, S.Hyman, RN,MPA,CIC, E. Y. Furuya, MD, S. Glied, PhD, E. Larson, RN, PhD, A Comparison of Methods to Detect Urinary Tract Infections Using Electronic Data, The Joint Commission Journal of Quality and Patient Safety.
S. Hyman, RN, MPA, CIC, P. Bernstein, BSN, RN, CIC, S. Shim, RN, BSN, CNOR., M. Messina, RN, BSN, P. Angevine, MD, MPH, et.al. A Multidisciplinary Approach to Surgical Site Infection Reduction, Association for Infection Prevention, New Orleans, Louisiana
M. Apte, MBBS,MsPH, T. Landers, CNP, PhD, E. Y. Furuya, MD, MS, S. Hyman,RN, MPA, CIC, E. Larson, RN, PhD, A Comparison of Performance of Two Computer Algorithms to Identify Surgical Site Infections Using Electronic Data, Association for Infection Prevention, New Orleans, Louisiana
B. Ross, RN, BSN, CIC, R. Chaudry, MS, S. Hyman, RN, MPA,CIC, F. Hong, MA, M. Fracaro, RN, MA, CIC, B. Forman, MD, M. Behta,PharmD,A Solution for New York State's Public Reporting Requirement: An Automated Surveillance System for Central Line-Associated Bloodstream Infections (CLABSI), Annual NPSF Safety Congress, Nashville, Tennessee
E. Y. Furuya, MD, H. Cook, MPH, H. Lee, BS, M. Miller, Ph.D, E. Larson, PhD, S. Hyman, RN, MPA, CIC, P. Della-Latta, PhD, E. Mendonca, MD, Ph. D., and F. Lowy, MD, Community-associated methicillin resistant Staphylococcus aureus prevalence: How common is it. A methodological comparison of prevalence ascertainment. American Journal of Infection Control, Volume 35 No. 6, 359-366.
S. Hyman, RN,MPA,CIC, P. Bernstein, RN, BSN, CIC, N. Schneider, RN, MS, CIC, S. O'Sullivan, RN, BSN, CIC, A. Castellanos, MBA, "Operation Come Clean- A Novel Approach to Improving Hand Hygiene
Compliance", American Journal of Infection Control, Volume 35, Issue 5, Pages E107 –E108.
E. Chen, Ph.D, D. Wajngurt, MD, MA, K. Qureshi, S. Hyman, RN, MPA, G. Hripcsak, MDS, MS, Automated Real-time Detection and Notification of Positive Infection Cases, American Medical Informatic Association Symposium.
D. Wajngurt MD, MA, .F. Hong, MA, R. Chaudry, MS, E. Hwang, MD, S. Hyman, RN, B. Ross, RN, M. Fracaro, RN , EpiPortal: An Electronic Decision Support System for Infection Control, American Medical Informatic Association Symposium.
JP Haas, RN, MS, D. Quiros, MS, SR, Hyman, MPA, EL Larson, RN, Ph.D, Use of an Innovative Game to Teach and Reinforce Hand Hygiene Compliance among Healthcare Workers, Association for Practitioners in Infection Control Conference and International Meeting.
Carey AJ, Graham PL, Hyman S, Carp D, Wu F, Della-Latta P, Rubenstein D, Saiman L. Molecular epidemiology of methicillin resistant Staphylococcus aureus in a level III-IV neonatal intensive care unit. Society of Pediatric Research, San Francisco, CA
EY Furuya, H. Cook, S. Hyman, et. al., Prevalence of Community-Associated Methicillin-Resistant Staphylococcus aureus: Methodology-Based Disparities. Interscience Antimicrobial Agents and Chemotherapy Conference
Hyman S, Wajngurt D, Hwang E, Furuya EY, Hong F, Fracaro M, Hammer S, Shortliffe E et al. Model for Designing Advanced Technological Tools to Enhance Infection Control Surveillance. Society for Healthcare Epidemiologists of America.
Hyman et al. Streamlining Daily Infection Control Surveillance: Implementation Of A Novel Information System At The Columbia University Medical Center. Society for Healthcare Epidemiology of America.
Marino, P, RN, Franco, M., MD, Hyman, S, RN "Community Acquired Pneumonia., Qualidigm Poster Presentation, Waterbury, CT
Sabetta, JR, MD, Hyman, SR, MPA,CIC, Smardin, J., CIC, "Foodborne Nosocomial Outbreak of Salmonella reading - Connecticut"MMWR, and JAMA, December 25,1991.
177 Fort Washington Avenue
Milstein 3GN Room 432
Tel: 212-305-4611
Fax: 212-305-8292
Jessica Justman, MD
Associate Professor of Medicine in Epidemiology at CUMC
Yale University, BS, 1981
University of Rochester, MD, 1985
SPECIALTY:HIV epidemiology, HIV prevention clinical research, metabolic complications of antiretroviral therapy
Dr. Justman's research interests focus on HIV prevention, with a focus on microbicides and other aspects of HIV in women, international HIV epidemiology and combination HIV prevention studies, as well as the metabolic complications of HIV. She established and continues to lead the Bronx-Lebanon HIV prevention clinical research site which conducts NIH-funded HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN) studies, such as HPTN 064, the Women's HIV Seroincidence Study, and MTN 014, a pharmacokinetic study of vaginal versus rectal use of reduced-glycerin tenofovir gel. Dr. Justman is also a principal investigator of three international studies: the Swaziland HIV Incidence Measurement Survey, an observational study of a household-based, nationally representative cohort to assess the national impact of male circumcision and other HIV prevention programs in Swaziland; and two assessments of district-wide combination HIV prevention programs, one in Sinazongwe, Zambia and one in Bukoba, Tanzania.
At the Mailman School of Public Health (MSPH), as Senior Technical Director at ICAP, she oversees technical assistance for the clinical and strategic information activities needed for HIV programs and health systems strengthening. From 2008 to 2010, Dr. Justman chaired the New York State Department of Health AIDS Institute's committee on clinical guidelines for adults with HIV.
J. Justman, A. Goldberg, J. Reed, N. Bock, E. Njeuhmeli, A.G. Thomas. Adult male circumcision: reflections on successes and challenges. J Acquir Immune Defic Syndr. 2013. 63 Suppl 2:S140-3.
C.W. Hendrix, B.A.Chen, V. Guddera, C. Hoesley, J. Justman, C. Nakabiito, R. Salata, L. Soto-Torres, K. Patterson, A.M. Minnis, S.Gandham, K. Gomez, J. Schwartz, B.A. Richardson, N. Bumpus. MTN-001: Pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013 8(1):e55013.
S.L. Hodder, J.Justman, J. Hughes , J. Wang, D.F. Haley, A.A. Adimora, C.Del Rio, C.E. Golin, I. Kuo, A. Rompalo, L. Soto-Torres, S.B. Mannheimer, L. Johnson-Lewis, S.H. Eshleman, W.M. El-Sadr. HIV Acquisition Among Women from Selected Areas of the United States. Ann Intern Med. 2013 158:10-18.
S.H. Eshleman, J.P. Hughes, O. Laeyendecker, J. Wang, R. Brookmeyer, L. Johnson-Lewis, C.E. Mullis, J. Hackett, A.S. Vallari, J. Justman, S.L. Hodder. Use of a multi-faceted approach to assess HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis. 2013. 207:223-31.
Chin CD, Laksanasopin T, Cheung YK, Steinmiller D, Linder V, Parsa H, Wang J, Moore H, Rouse R, Umviligihozo G, Karita E, Mwambarangwe L, Braunstein SL, van de Wijgert J, Sahabo R, Justman JE, El-Sadr W, Sia SK. Microfluidics-base diagnostics of infectious diseases in the developing world. Nat Med. 2011 17:1015-9.
Hodder SL, Justman J, Haley DF, Adimora AA, Fogel CI, Golin CE, O'Leary A,Soto-Torres L, Wingood G, El-Sadr WM; HIV Prevention Trials Network Domestic Prevention in Women Working Group. Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr. 2010 55 Suppl 2:S69-73.
B. Cutler, J. Justman. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008 11:685-97.
M.E. Sobieszczyk, D.R. Hoover, K. Anastos, K. Mulligan, T. Tan, Q. Shi, W. Gao, C. Hyman, M.H. Cohen, SR. Cole, M.W. Plankey, A.M. Levine, J. Justman. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008 48:272-80.
J.E. Justman, D.R. Hoover, Q. Shi , T. Tan, K. Anastos, P.C. Tien ,S.R. Cole, C. Hyman , R. Karim, K. Weber, S. Grinspoon. Longitudinal anthropometric patterns among HIV-infected and –uninfected women. JAIDS 2008 47: 312-9.
K.H. Mayer, L.A.Maslankowski, F. Gai, W.M. El-Sadr, J. Justman, A. Kwiecien, B. Masse, S.H. Eshleman, C. Hendrix, K. Morrow, J.F. Rooney, L. Soto-Torres. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006. 20:543-51.
J.E. Justman, L. Benning, A. Danoff, H. Minkoff, A. Levine, R.M. Greenblatt, K. Weber, E. Piessens, E. Robinson, K. Anastos. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003 32:298-302.
722 W 168th Street, Room 1315
Columbia University Medical Center
New York, New York 10032
Tel: 212-342-0537
E-mail: firstname.lastname@example.com
NAME: Charles Knirsch, MD, MPH
Adjunct Assistant Professor of Medicine
University, BSc, 1981
McGill University, MD, 1985
Columbia University, MPH, 1995
SPECIALTY: TB, travel medicine
Charles Knirsch, MD, MPH research has
integrated work with several Public-Private-Partnerships to collaborate
on disease control and elimination programs. This has involved work on
addressing information management for tuberculosis patient treatment
protocols and hospital epidemiology in New York to more recent
international sector collaborations on malaria with The National Institutes
of Health and The Centers for Disease Control and Prevention. Chuck
currently collaborates with The World Health Organization and The
International Trachoma Initiative on a program to eliminate blinding
trachoma by the year 2020.
El-Tahtawy A, Glue P, Andrews
EN, Mardekian J, Amsden GW, Knirsch CA. The Effect of Azithromycin on
Ivermectin Pharmacokinetics – A Population Pharmacokinetic Model
Analysis. PLoS Negl
Trop Dis. 2008 May 14;2(5):e236.
Knirsch C. Trachoma: ancient
scourge, disease elimination, and future research.
Curr Infect Dis Rep.
2007 Jan;9(1):21-8.
Noedl H, Krudsood S,
Leowattana W, Tangpukdee N, Thanachartwet W, Looareesuwan S, Miller RS,
Fukuda M, Jongsakul K, Yingyuen K, Sriwichai S, Ohrt C, Knirsch C. In vitro antimalarial activity of azithromycin, artesunate, and quinine in
combination and correlation with clinical outcome. Antimicrob Agents Chemother.
2007 Feb;51(2):651-6.
Noedl H, Krudsood S,
Chalermratana K, Silachamroon U, Leowattana W, Tangpukdee N, Looareesuwan
S, Miller RS, Fukuda M, Jongsakul K, Sriwichai S, Rowan J, Bhattacharyya
H, Ohrt C, Knirsch C. Azithromycin combination therapy with artesunate or
quinine for the treatment of uncomplicated Plasmodium falciparum malaria
in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis. 2006
Nov 15;43(10):1264-71.
Mecaskey JW, Knirsch CA,
Kumaresan JA, Cook JA. The possibility of eliminating blinding trachoma. Lancet Infect Dis.
2003 Nov;3(11):728-34.
Barr RG, Diez-Roux AV, Knirsch
CA, Pablos-Méndez A. Neighborhood poverty and the resurgence of
Tuberculosis in New York City, 1984 to 1992. Am J Public Health 2001
Hripcsak G, Knirsch CA, Jain
N, Stazesky RC, Pablos-Mendez A, Fulmer T. A health information network
for managing inner-city Tuberculosis: Bridging clinical care, public
health, and home care. Computers
and Biomedical Research 1999 Feb;32 (1):67-76.
Knirsch CA, Jain NL,
Pablos-Mendez A, Friedman C, Hripcsak G. Tuberculosis Detection and
Monitoring by an Automated Clinical Decision Support System. Infect Control Hosp Epidemiol 1998;19 (2) 94-100.
Pablos-Mendez A, Blustein J,
Knirsch CA. The role of diabetes mellitus in the higher prevalence of
tuberculosis among Hispanics. Am
J Public Health 1997; 87:574-579.
Pablos-Mendez A, Knirsch CA, Barr
RG, Lerner BH, Frieden TR. Noncompliance with antituberculosis treatment:
Predictors and consequences in New York City. Am J Med 1997;102:164-170.
Pfizer Inc.
235 East 42nd Street
New York, NY 10017
Christine J. Kubin, PharmD, BCPS (AQ-ID)
Assistant in Medicine
University of North Carolina at Chapel Hill, PharmD, 1998
SPECIALTY: Anti-infective pharmacology and therapeutics, antimicrobial
resistance and epidemiology
Dr. Kubin is the Clinical Pharmacy Manager in the Division of Infectious Diseases at NewYork–Presbyterian Hospital, Columbia University Medical Center and a board-certified pharmacotherapy specialist with added qualifications in infectious diseases. Her research interests focus on anti-infective treatment outcomes and the epidemiology of multi-drug resistant pathogens. Dr Kubin is a member of the joint Anti-Infective Subcommittee at NewYork–Presbyterian Hospital and co-spearheads antimicrobial stewardship activities with Dr. Furuya. Current projects include evaluating treatment outcomes and therapies for infections caused by carbapenem-resistant organisms with a specific focus on optimal polymyxin B regimens and dosing. She is also currently working on optimizing outcomes in patients with Clostridium difficile infection, evaluating the relationships of antibiotic utilization and resistance within the hospital, and minimizing surgical site infections.
Kubin CJ, Jia H, Alba LR, Furuya EY: Lack of significant variability among different methods for calculating antimicrobial days of therapy. Infect Control Hosp Epidemiol 33 (Special Topic Issue: Antimicrobial Stewardship): 421-3, 2012.
Thomas TA, Broun EC, Abildskov KM, Kubin CJ, Horan J, Yin MT, Cremers S. High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 2012 Aug;34(4):398-405.
Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65(1):80-7.
Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011; 55(12):5893-9.
Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest.J Clin Microbiol 2011; 49(5):1795-8.
Kubin CJ, Mehta M. Influenza vaccine and treatment update. US Pharm 2010; 35(8):28-42.
Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Medical Mycology 2010; 48(2):436-9.
Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010; 67(2):180-4.
Kubin CJ. Antimicrobial stewardship programs: role in optimizing infectious disease outcomes. Disease Management and Health Outcomes 2008; 16(6): 403-410.
Patel SJ, Larson EL, Kubin CJ, Saiman L. A review of antimicrobial control strategies in hospitalized and ambulatory pediatric populations. Pediatr Infect Dis J 2007; 26(6):531-537.
Kubin CJ, Dzierba A. The effects of continuous renal replacement therapy (CRRT) on anti-infective therapy in the critically ill. Journal of Pharmacy Practice 2005; 18: 109-117.
Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. Journal of Antimicrobial Chemotherapy 2004; 54(2): 566-9.
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: email@example.com
Franklin D. Lowy, MD
Professor of Medicine and Pathology & Cell Biology
Columbia College BA, 1968
Columbia University College of Physicians and Surgeons, MD, 1972
SPECIALTY: Internal Medicine and Infectious
Dr. Franklin Lowy's laboratory investigates the pathogenesis and epidemiology of Staphylococcus aureus and Staphylococcus epidermidis infections.
Studies on the pathogenesis of staphylococcal infections: Recent projects have focused on the role of different S. aureus and S. epidermidis surface proteins as mediators of adherence to prosthetic device material such as that used in ventricular assist devices. The goal of these studies is to characterize the role of these proteins in the initiation of device-related infections. A second series of studies have used a mouse post-influenza S. aureus pneumonia model to investigate the pathogenesis of these life-threatening infections.
Studies on the transmission of S. aureus among high-risk populations: These large-scale population-based studies integrate classic epidemiologic methods with molecular epidemiologic techniques, including whole genome sequencing, to define the spread of epidemic strains of S. aureus within high-risk populations. A household-based study is underway to investigate how community-associated methicillin-resistant S. aureus (CA-MRSA) is spread in the predominantly Dominican population that surrounds Columbia University Medical Center. The goal of these studies is to gain a better understanding of the epidemiologic and bacterial genetic factors that contribute to the dissemination of S. aureus within urban populations. A second component of this investigation is to examine the spread of a unique methicillin-susceptible S. aureus, strain ST398. This strain is prevalent in Northern Manhattan and is responsible for an increasing number of clinical infections.
Lowy, F.D. Staphylococcal Infections In: Harrison's Principles of Internal Medicine, 18th edition. Editors: A. S. Fauci, E. Braunwald, D.L. Casper, S. L. Hauser, D. L. Longo, J. L. Jameson and J. Loscalzo. The McGraw-Hill Companies, Inc., In Press 2013
Gordon, R.J., Weinberg, A.D., Pagani F.D., Slaughter, M.S., Pappas, P.S., Naka, Y., Goldstein, D.J., Dembitsky, W.P., Giacalone, J.C., Ferrante, J., Ascheim, D.D., Moskowitz, A.J., Rose, E.A., Gelijns, A.C., Lowy, F.D. A prospective, multicenter study of ventricular assist device infections. Circulation 127(6):691-702, 2013
Uhlemann, A-C, Kennedy, A.D., Martens, C., Porcella, F.C. DeLeo, F.R. and Lowy, F.D. Towards an understanding of evolution of Staphylococcus aureus strain USA300 during colonization in community households. Genome Biology and Evolution. Genome Biol Evol. 12:1275-85, 2012
Gwizdala, R., Miller, M., Bhat, M., Vavagiakis, P., Henry, C., Neaigus, A., Shi, Q. and Lowy, F.D. Staphylococcus aureus among drug users: identification of hidden networks. Amer. J. Pub. Health. In Press 2011
Lee M.H., Arrecubieta C., Martin F.J., Prince A., Borczuk A.C. and Lowy F.D. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 201:508-15, 2010
Arrecubieta, C., Francis, F.A.T.,von Bayern, M. P., Akashi, H., Deng, M.C., Naka, Y. and Lowy, F.D. SdrF, a Staphylococcus epidermidis surface protein, contributes to the initiation of ventricular assist device driveline-related infections. PLoS Pathogens 5:e1000411-1000424, 2009
Lowy, F. D. Secrets of a superbug. Nat. Med.13:1418-1420, 2007
Arrecubieta, C., Lee, M., Macey, A., Foster, T.J. and Lowy, F.D. SdrF, a Staphylococcus epidermidis surface protein, binds type 1 collagen. J. Biol. Chem. 282:18767-18776, 2007
Lowy, F.D., Aiello, A.E., Bhat, M., Johnson-Lawrence, V.D., Lee, M., Burrell, E., Wright, L.N., Vasquez, G. and Larson, E.L. Staphylococcus aureus colonization and infection in New York State Prisons. J. Infect. Dis. 196:911-918, 2007
Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis. 2006;6:426-37
Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nature Microbiol Rev. 2006;4:36-45
Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest. 2003;111:1265-1273
Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, 9-458
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-5794
E-mail: email@example.com
NAME: Wendy
McGahee, MD
Adjunct Instructor in Clinical Medicine
Long Island University, BS, 1985
Morehouse School of Medicine, MD, 1995
SPECIALTY: General infectious diseases, substance abuse
St. Luke's–Roosevelt Hospital Center
Addiction Institute of New York
Clark 6–Detoxification Unit
1111 Amsterdam Avenue
New York, NY 10025
E-mail: email@example.com
Assistant Professor of Medicine
Boston University, BA, 2003
Boston University School of Medicine, MD, 2006
Columbia University Mailman School of Public Health, MS, 2012
Infectious diseases in immunocompromised hosts, staphylococcal infections, general infectious diseases, HIV primary care, MRSA molecular epidemiology
Dr. Benjamin A. Miko is Assistant Professor of Medicine at Columbia University Medical Center in the Division of Infectious Diseases. His research interests focus on the molecular epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) in both healthcare and community settings. His previous studies have evaluated the role of environmental contamination and multiple body site colonization on the risk of S. aureus transmission and infection. He remains engaged in research to reduce the incidence of staphylococcal infections in New York State maximum security prisons. Dr. Miko's clinical interests include management of infectious complications of solid organ transplantation, bone marrow transplantation, and hematological malignancies. He also specializes in the treatment of staphylococcal infections, general infectious diseases, and HIV/AIDS.
Uhlemann AC, Hafer CA, Miko BA, Sowash M, Sullivan SB, Shu Q, Lowy FD. Emergence of ST398 as a community and healthcare-associated methicillin-susceptible Staphylococcus aureus in Northern Manhattan. Clin Infect Dis. In Press.
Miko BA, Herzig CTA, Mukherjee DV, Befus M, Apa ZL, Bai RY, Lee CJ, Uhlemann AC, Larson EL, Lowy FD. Is Environmental Contamination Associated with Staphylococcus aureus Clinical Infection in Maximum Security Prisons? Infect Control Hosp Epidemiol. 2013;34:540-2.
Miko BA, Hafer CA, Lee CJ, Sullivan SB, Hackel MAM, Johnson BM, Whittier S, Della-Latta P, Uhlemann AC, Lowy FD. Molecular Characterization of Methicillin-Susceptible Staphylococcus aureus Clinical Isolates in the United States, 2004 to 2010. J Clin Microbiol. 2103;54:874-9.
Miko BA, Uhlemann AC, Gelman A, Lee CJ, Hafer CA, Sullivan SB, Shi Q, Miller M, Zenilman J, Lowy FD. High prevalence of colonization with Staphylococcus aureus clone USA300 at multiple body sites among sexually transmitted diseases clinic patients: An unrecognized reservoir. Microbes Infect. 2012;14:1040-3.
Miko BA, Cohen B, Conway L, Gilman A, Seward SL, Larson E. Determinants of Personal and Household Hygiene among College Students in New York City, 2011. Am J Infect Control. 2012;40:940-5.
Lat A, Bhadelia N, Miko B, Furuya EY, Thompson GR. Invasive Aspergillosis After Pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16:971-973.
Sandora TH, Desai R, Miko BA, Harper MB. Assessing quality indicators for pediatric community-acquired pneumonia. Am J Med Qual. 2009;24:419-427.
Selected Abstracts:
Miko BA, Befus M, Herzig CTA, Mukherjee DV, Apa ZL, Bai RY, Tanner JP, Gage D, Genovese M, Koenigsmann CJ, Larson EL, Lowy FD. Risk Factors for Staphylococcus aureus Clinical Infection in New York State Maximum Security Prisons. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy – Denver, Colorado, 2013.
Herzig C, Uhlemann AC, Jeon C, Lee C, Miko B, Mukherjee D, Befus M, Jia H, Larson E, Lowy F. The Impact of Inter-Facility Prison Inmate Transfer on Methicillin-Resistant Staphylococcus aureus Transmission in the New York State Correctional System. Society for Epidemiologic Research Annual Meeting – Boston, Massachusetts, 2013.
Uhlemann AC, Miko BA, Hafer CA, Sowash M, Shi Q, Lowy FD. Epidemiology of Animal-Independent ST398 Methicillin-Susceptible Staphylococcus aureus in Northern Manhattan. IDWeek – San Diego, California, 2012.
Uhlemann AC, Hafer CA, Miko BA, Sowash M, Shi Q, Lowy FD. Emergence of ST398 MSSA as community- and healthcare-associated Staphylococcus aureus in Northern Manhattan. International Symposium on Staphylococci and Staphylococcal Infections – Lyon, France, 2012.
Haxall K, Cohen B, Miko BA, Conway L, Kelly N, Stare D, Troiano C, Gilman A, Seward S, Larson E. Personal and Household Hygiene, Microbial Contamination, and Health Status in Undergraduate Residence Halls in New York City. Association for Professionals in Infection Control and Epidemiology Annual Meeting - San Antonia, Texas, 2012.
Miko B, Hafer C, Lee C, Sullivan S, Hackel M, Johnson B, Uhlemann AC, Lowy F. Molecular Characterization of American Methicillin-Susceptible Staphylococcus aureus Infectious Isolates, 2004-2010. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy – Chicago, Illinois, 2011.
Miko B, Ulhemann AC, Gelman A, Lee C, Hafer C, Sullivan S, Miller M, Zenilman J, Lowy F. High Prevalence of Genital Colonization with Staphylococcus aureus USA300 Clone. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy – Chicago, Illinois, 2011.
Pereira M, Miko B, Fatehi P, Sobieszczyk M. Prevalence of Chronic Kidney Disease in an HIV-Infected Latino Urban Population. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting – Washington, DC, 2008.
NAME: Ellen Morrison, MD, MPH
Assistant Professor of Clinical Medicine and Clinical Epidemiology
Olivet Nazarene College, BA, 1979
Washington University School of Medicine, MD, 1984
Columbia University Mailman School of Public Health, MPH, 1996
General infectious diseases, HIV/AIDS, sexually transmitted diseases, infections in pregnancy. Dr Morrison was the program director for the Nicholas A. Rango HIV Scholar's program, a postgraduate training program in ambulatory HIV care, at New York–Presbyterian Hospital for more than 10 years. She is the medical director of the HIV Counseling and Testing Service at New York–Presbyterian Hospital and is Chair of the Quality Improvement and Patient Safety committee for the Comprehensive HIV Program at New York-Presbyterian Hospital.
Dr. Morrison has research interests in the areas of HIV testing and linkage to care, and HIV treatment and disease.
Christopoulos KA, Schackman BR, Lee G, Green RA, Morrison EA.Results from a New York City Emergency Department Rapid HIV Testing Program. JAIDS 2010;53:420-2.
Morrison EAB and Levenson J.Medical Treatment and Occupational Exposure.In:Fernandez F and Ruiz P, eds.Psychiatric Aspects of HIV/AIDS.Philadelphia: Lippincott Williams and Wilkins; 2006:23-35.
Morrison EAB et al. Development of a multi-item scale to quantitatively assess sexual behaviors and the transmission of high and low risk human papillomaviruses. Sex Trans Dis. 1998;25:509-515.
Morrison EAB et al. Low prevalence of cervical human papillomavirus infection in renal transplant recipients. Neph Dial Trans. 1996:1603-1606.
Morrison EAB et al. Pregnancy and cervical infection with human papillomaviruses. Int J Gyn Obstet. 1996;54:125-130.
Morrison EAB et al. Quantitation may improve clinical utility. J Clin Micro. 1992;30:2539-2543.
Morrison EAB et al. Self-administered home cervicovaginal lavage: A novel tool for the clinical/epidemiological investigation of genital HPV Infections. Am J Obstet Gynecol. 1992;167:104-107.
Morrison EAB et al. Human papillomavirus infection and other risk factors for cervical neoplasia: A case control study. Int J Cancer. 1991;49:6-13.
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-6328
E-mail: firstname.lastname@example.com
NAME: Julie E. Myers, MD, MPH
ACADEMIC TITLE: Instructor in Clinical Medicine
Yale University, B.S. (Biology), 1996
Weill Medical College of Cornell University, M.D., 2003
Columbia Mailman School of Public Health, M.P.H. in Epidemiology, 2011
SPECIALTY: HIV therapy and HIV prevention
Dr. Myers is an Instructor in Clinical Medicine in the Division of Infectious Diseases. She holds the position of Director of Policy and Program Planning in HIV Prevention in the Bureau of HIV/AIDS Prevention and Control at the New York City Department of Health and Mental Hygiene. Dr. Myers' primary research interests include biomedical HIV prevention and various aspects of HIV testing, including the use of self-testing. She is also involved in a long-standing collaboration with an HIV treatment program in the Dominican Republic where she investigated treatment outcomes among HIV-infected individuals entering care.
Myers JE, Sepkowitz KA. A Pill for HIV Prevention: Deja Vu All Over Again? Clin Infect Dis. 2013, in press.
Myers JE, El-Sadr WM, Zerbe A, Branson BM. Rapid HIV self-testing: long in coming but opportunities beckon. AIDS 2013, in press.
Rucinski KB, Mensah NP, Sepkowitz KA, Cutler BH, Sweeney MM, Myers JE. Knowledge and Use of Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in New York City. AIDS Behav. 2013, in press.
Myers JE, Braunstein SL, Shepard CW, Cutler BH, Mantsios A, Sweeney MM, Tsoi BW. Assessing the impact of a community-wide HIV testing scale-up initiative in a major urban epidemic. JAIDS 2012;61(1):23-31.
Jenness S, Myers JE, Neaigus A, Lulek J, Navejas M, Raj-Singh S. Delayed Entry into HIV Medical Care after HIV Diagnosis. AIDS Care 2012; 24(10):1240-8.
Kim EK, Thorpe L, Myers JE, Nash D. Healthcare-related correlates of recent HIV testing in New York City. Prev Med. 2012;54(6):440-3.
Myers JE, Myers R, Wheat M, Yin MT. Dental students and blood-borne pathogens: occupational exposures, knowledge, attitudes. J Dent Edu. 2012;76(4):479-86.
Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Coakley E, Lie Y, Hammer SM, Brudney KF. Transmitted drug-resistance among antiretroviral naïve patients with established HIV-1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Hum Retroviruses. 2012;8(7):667-74.
Myers JE, Tsiouris SJ. Is there a place for directly observed therapy in HAART? Lancet. 2009;374:2030-2032.
Frieden TR, Myers JE, Krauskopf MS, Farley TA. A Public Health Approach to Winning the War Against Cancer. Oncologist. 2008; 13:1306-1313.
Myers JE, Frieden TR, Bherwani KM, Henning KJ. Privacy and Public Health at Risk: Public Health Confidentiality in the Digital Age. Am J Public Health. 2008,98(5):2-9.
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, P&S Box 82
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: email@example.com
Susan Olender, MD
Assistant Professor in Clinical Medicine
SUNY at Albany, BA, 1994
NYU School of Medicine, MD, 2002
SPECIALTY: HIV primary
Schnall R, Clark S, Olender S, Sperling JD. Providers' perceptions of the factors influencing the implementation of the New York State mandatory HIV testing law in two Urban academic emergency departments. Acad Emerg Med. 2013 Mar;20(3):279-86.
Olender S, Wilkin TJ, Taylor BS, Hammer SM. Advances in antiretroviral therapy. Topics in Antiviral Medicine, 2012; 20:61-86.
Shalev N, Olender SA, Chiasson MA. "Targeted anal cancer screening in HIV-infected patients: prevalence of screening indicators." AIDS, 2009;23(12):1613-5.
Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients. AIDS, 2008; 22(8):947-55.
Wilkin TJ, Taylor B, Olender S, Hammer SM. "Advances in Antiretroviral Therapy." Topics in HIV Medicine, 2008; 16:31-60. http://www.iasusa.org/pub/topics/2008/issue1/31.pdf
Chiasson MA, Massad LS, Olender S, Wright TC. HIV Infection in Women in Atlas of AIDS. Mandell GL and Mildvan D editors, Fourth Edition. Current Medicine, 2007.
Olender S, Saito M, Apgar J, Gillenwater K, Bautista CT, Lescano AG, Moro P, Caviedes L, Hsieh EJ, Gilman RH. Low prevalence and increased household clustering of Mycobacterium tuberculosis infection in high altitude villages in Peru. American Journal of Tropical Medicine and Hygiene, 2003; 68:721-727.
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-3174
Fax: 212-305-7692
E-mail: email@example.com
NAME: Michael Parry, MD
Adjunct Professor of Clinical Medicine
Yale University, BA, 1966
Columbia College of Physicians and Surgeons, MD, 1970
SPECIALTY: General infectious diseases, hospital epidemiology and infection prevention, travel medicine
Tejwani, R and Parry, MF.Antimicrobial Lock Therapy as an Adjunct to Management of Catheter-related Bacteremia:A Community Hospital Experience.Infectious Diseases in Clinical Practice.2011:19,256-261.
Carling, PC., Parry, MF, Bruno-Murtha, LA, Dick, B.Improving Environmental Hygiene in 27 Intensive Care Units to Decrease Multidrug-Resistant Bacterial Transmission.Critical Care Medicine 2010. 38:1054-1059.
Carling, PC., Parry, MF, Rupp, ME; Po,JL, Dick, B, Von Beheren, S. Improving Cleaning of the Environment Surrounding Patients in 36 Acute Care Hospitals.Infection Control and Hospital Epidemiology 2008.29:1035-1041.
Polgreen, P.M., Septimus, E.J., Parry, M.F., Beekman, S.E., Cavanaugh, J.E., Srinivasan, A., Talbot, T.R.Relationship of Influenza Vaccination Declination Statements and Influenza Vaccination Rates for Healthcare Workers in 22 US Hospitals.Infection Control Healthcare Epidemiology 2008.29:675-677.
Kritchevsky, S.B., Braun, B.I., Kusek, L., Wong, E.S., Solomon, S.L., Parry, M.F., Richards, C.L. and Simmons, B.S.The Impact of Hospital Practice on Central Venous Catheter-associated Bloodstream Infection Rates at the Patient and Unit Level: a Multi-center Study.American J Medical Quality 2008. 23:24-38.
Parry, M.F., Wright, P., Stewart, J.,McLeod, G.X., Tucker, M., and Weinberg, A.Impact of an Adherence Program on the Health and Outlook of HIV-Infected Patients Failing Antiretroviral Therapy.Journal of the International Association of Physicians in AIDS Care.2005. 4:59-65.
Parry, M.F., Grant, B., Iton, A., Parry, P.D., Baranowsky, D.Influenza Vaccination – A Collaborative Effort to Improve the Health of the Community.Infection Control and Healthcare Epidemiology.2004; 25:929-932.
Parry, M.F., Grant, B., Yukna, M., Adler-Klein, D., McLeod, G., Rosenstein, C., and Taddonio, R.Candida Osteomyelitis and Diskitis after Spinal Surgery.An Outbreak that Implicates Artificial Nail Use. Clin Infect Dis.32:352-357, 2001.
Stamford Hospital
30 Shelburne Road
Stamford, CT 06904
Tel: 203-
E-mail: email@example.com
NAME: Marcus R. Pereira, MD, MPH
ACADEMIC TITLE: Assistant Clinical Professor of Medicine
New College of Florida BS, 1999
Florida International University MPH, 2000
University of Florida MD, 2004
SPECIALTY: Transplant infectious diseases, General infectious diseases, HIV primary care
Dr. Marcus Pereira is an Assistant Clinical Professor of Medicine at the Columbia University College of Physicians. During fellowship at Columbia University, he studied the prevalence and risk factors for chronic kidney disease among patients in our HIV clinic. He also joined Dr. Fidock's laboratory to study malaria drug resistance and in vivo PK/PD trials of antimalarial drug combinations. Spearheading the Transplant Infectious Diseases Program, Dr. Pereira is focused on infectious complications among transplant patients in both inpatient and outpatient settings. He is also involved in the development of infection prophylaxis and treatment protocols in immunocompromised patients. His current research includes multi-drug resistant infections, including bacterial and fungal organisms among renal and liver transplant patients.
Brown RS Jr, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, Buti M, Fagan EA. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012 Jul 2.
Pouch S, Kubin C, Tsapepas D, Dube G, Pereira MR; Epidemiology and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Bacteriuria in Renal Transplant (RT) Recipients; ICAAC 2012: T- 1034
Kubin C, Pouch S, Tsapepas D, Dube G, Pereira MR; Epidemiology and Antimicrobial Resistance in Urine Isolates Among Renal Transplant Recipients Over a 10-year Period; ICAAC 2012; T-1036
Chan G, Austin E, Cheung S, Sobieszczyk M, Pereira MR: Incidence of and Risk Factors or Chronic Kidney Disease in an HIV-Infected Ethnic Minority Urban Population; International AIDS Conference 2012: MOPE088
Pereira MR, Henrich P, Sidhu A, Johnson D, Hardink J, Van Deusen J, Lin J, Gore K, O'Brien C, Wele M, Djimde A, Chandra R, Fidock DA. In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. Antimicrob Agents Chemother. 2011 Jul;55(7):3115-24. Epub 2011 Apr 4.
Pereira MR, Liao, J, Fidock DA: Potentiation of Chloroquine and Azithromycin by (+)-Amlodipine in a Chloroquine-Resistant Rodent Malaria Model; ICAAC 2009: P-366
Kumar STR, Pereira MR, Fidock DA: Inhibitors of FabI as Potential Antimalarial Prophylactic Agents; ASTMH 2009: # 520
Pereira MR, Miko B, Fatehi P, Brudney K, Sobieszczyk M: Prevalence and Risk Factors of Chronic Kidney Disease in an HIV Infected Minority Population; IDSA/ICAAC 2008; H-2340
630 W 168th Street, Box 82
New York, New York 10032
Tel: 212-305-7185 / 212-570-3081
E-mail: firstname.lastname@example.com
NAME: Deborah Rudin, MD
Assistant Professor of Clinical Medicine
University of Pennsylvania, BA, 1983
Mount Sinai School of Medicine, MD, 1987
SPECIALTY: Vaccine product development
Global Medical Director
Product Leader-Pediatric Vaccines
Global Medical Affairs, Information and Operations
Office Number: 908-423-5072
Columbia University Medical Center
630 W 168th Street, Box 82
New York, New York 10032
Tel: 212-305-7185
Brian Scully, MD
Associate Professor of Clinical Medicine
Trinity College, Dublin University, BA, 1969
Trinity College, Dublin University, MB, BCh, BAO, 1971
Trinity College, Dublin University, MA, 1973
SPECIALTY: Nosocomial infections, transplant infectious disease
Dr Scully is the chair of the Infection Control Committee at
NewYork–Presbyterian Hospital, and cochair of the Joint Infection Control
Committee and the Joint Subcommittee on Anti-infective Use. His research
interests are in nosocomial infections, transplant infectious disease,
and hospital epidemiology.
Farr M, Rubin AI, Mangurian C, Scully B et al. Late syphilis in cardiac transplant patient. J Heart Lung Transplant. 2006 25(3): 358-61.
Haas S, Scully B, Cohen D, Radhakrishnan J. Mycobacterium avium complex infection in kidney transplant patients. Transpl Infect Dis. 2005 7(2):75-9.
Lux JZ et al. Transfusion-associated babesiosis after heart transplant. Emerg Infect Dis. 2003;9:116-119.
Saiman L et al. Banning artificial nails from health care settings. Am J Infect Control. 2002;11:252-254.
Knirsh CA et al. An outbreak of Legionella micdadei pneumonia in transplant patients: Evaluation, molecular epidemiology, and control. Am J Med. 2000;108:290-295.
Sinha et al. Infections during left ventricular assist device support do not affect postransplant outcomes. Circulation. 2000;102III:194-199.
Argenziano et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant. 1997;16:822-831.
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
NAME: Noga Shalev, MD
Assistant Professor of Medicine
University of California, Berkeley, BA, 1996
NYU School of Medicine, MD, 2003
SPECIALTY: HIV primary care, correctional medicine
Dr. Noga Shalev is an Assistant Professor in Clinical Medicine in the Infectious Diseases Division at the Columbia University College of Physicians. Her research focuses on the evaluation of medical care in correctional settings and its impact on health inequities.
Shalev N, Mackenzie S. Correlation between imprisonment rates and new HIV/AIDS diagnoses. Presented at the 19th International AIDS Conference, Washington, DC. July 2012.
Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era." Antivir Ther. 2012;17(5):785-92.
Ammassari A, Trotta MP, Shalev N, Tettoni MC, Maschi S, Di Sora F, Orofino G, d'Ettorre G, Bai F, Celesia MB, Roldan EQ, Maserati R, Sterrantino G, Tommasi C, Boumis E, Iardino MR, Antinori A. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(4):e113-5.
Shalev N, Chiasson MA, Dobkin JF, Lee G. Characterization of medical providers to jail inmates in New York State. Am J Public Health. Accepted for publication July 2010.
Shalev N, Olender SA, Chiasson MA. Targeted anal cancer screening in HIV-infected patients: prevalence of screening indicators.
AIDS. 2009 Jul 31;23(12):1613-5.
Shalev N From public to private care the historical trajectory of medical services in a New York city jail. Am J Public Health. 2009;99(6):988-95.
Kluger M, Shalev N, Capponi L, Heinzerling K. Designing a clinical hepatitis screening and prevention program. 4th National Harm Reduction Conference, Seattle, WA, December 2002
Heinzerling K, Shalev N. Brief interventions to reduce harmful injection practices among drug users in health care settings. 4th National Harm reduction Conference, Seattle, WA December 2002
Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D, McCormick F, Hass-Kogan DA. Transcription activation of TRADD mediated p53 independent radiation-induced apoptosis of glioma cells. Oncogene 2001;20:2826-35.
Shalev, N. Hepatitis Screening and vaccination at a syringe exchange. 3rd National Harm Reduction Conference, Plenary Session, Miami, FL, October 2000
Harkness Pavilion, 6th Floor
180 Fort Washington Avenue
New York, NY 10032
Tel: 212-305-4707
Fax: 212-305-7692
E-mail: email@example.com
NAME: Magdalena Sobieszczyk, MD, MPH
Assistant Professor of Clinical Medicine
Harvard University, BA, 1994
Columbia College of Physicians and Surgeons, MD, 1998
Columbia University Mailman School of Public Health, MPH, 2006
SPECIALTY: HIV vaccine trials, international HIV, metabolic complications of HIV therapy
Dr. Magdalena Sobieszczyk is an Assistant Professor of Clinical Medicine in the Infectious Diseases Division at the Columbia University College of Physicians. Her research focuses on biomedical HIV prevention strategies, specifically clinical trials of preventive HIV vaccines. Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical prophylactic antiretrovirals; and evaluating host factors influencing immunologic and virologic course of HIV disease and response to vaccination in study participants. As an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine, she has been involved in the development and implementation of several international and national protocols. For example, she is the co-chair of phase 2b HIV vaccine protocol to determine the safety and efficacy of the DNA prime-Ad5 boost vaccine regimen in individuals at risk of HIV infection (HVTN 505). She is also chairing an observational study evaluating virologic, immunologic, and clinical course of HIV infection in persons who participated in HIV vaccine trials (HVTN 802).
Dr. Sobieszczyk is also a co-investigator of the Centre for the AIDS Program of Research in South Africa (CAPRISA) project entitled "Viral Setpoint and Clinical Progression in HIV-1 Subtype C Infection: The Role of Immunological and Viral Factors During Acute and Early Infection" (Salim Abdool Karim, PI).
Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME. Translational Research Insights from Completed HIV Vaccine Efficacy Trials. Accepted Journal of AIDS 2013; (63) Supplement 2, July 1
Mlisana K, Sobieszczyk ME, Loggerenberg F, Feinstein A, Werner L, Feinstein A, Williamson C, Loggerenberg F, Karim S, CAPRISA 002 Acute HIV Infection Study Team. Challenges of diagnosing acute HIV-1 subtype C infection in African women: Performance of a clinical algorithm and the need for point-of-care nucleic acid based testing. PLoS ONE 2013; 8(4): e62928. doi:10.1371/journal.pone.0062928
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk MS, and Hammer SM. In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. AIDS Research and Human Retroviruses 2013. ahead of print. doi:10.1089/aid.2012.0385
Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, David B. Weiner DB, Baden LR. Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults. PLoS ONE 2012; 7(1): e29231. doi:10.1371/journal.pone.0029231
Loggerenberg F, Dieter AA, Sobieszczyk ME, Werner L, Grobler A, and Mlisana K. HIV prevention in high-risk women in South Africa: Condom use and the need for change. PLoS ONE 2012; 7(2): e30669. doi:10.1371/journal.pone.0030669
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe O, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath JM, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R. Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects. J Infect Dis 2011; 204 (10): 1541-1549
Sobieszczyk ME, Lingappa J, McElrath JM. Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr Opinion HIV/AIDS 2011; 6 (5): 427-434
Fuchs J, Sobieszczyk ME, Hammer S, Buchbinder S. Lessons Drawn From Recent HIV Vaccine Efficacy Trials. J Acquir Immune Defic Syndr 2010; 55(Suppl 2): S128-S131
Sobieszczyk ME., Xu G., Goodman K., Lucy D., Koblin BA. Engaging Members of Ethnic Minority Communities in Preventive HIV Vaccine Trials. J J Acquir Immune Defic Syndr 2009; 51(2):194-201
Mlisana K, Auld SC, Grobler A, van Loggerenberg F, Williamson C, Iriogbe I, Sobieszczyk ME, Abdool Karim SS; CAPRISA Acute Infection Study Team. Anaemia in acute HIV-1 subtype C infection. PLOS One, 2008; 3(2):e1626
Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The Challenge of HIV-1 Subtype Diversity. New England Journal of Medicine, 2008; 358:1590-1602
Sobieszczyk ME, Taylor B, Hammer SM. Antiretroviral Agents. In Clinical Virology, Richman Whitley, Hayden, Third Edition, 2008.
Sobieszczyk ME, D.R. Hoover, K. Anastos, K. Mulligan, T. Tan, C. Hyman, M.H. Cohen, S.R. Cole, J. Justman, Women's Interagency HIV Study. Prevalence and predictors of metabolic syndrome among HIV-positive and negative women. J Acquir Immune Defic Syndr, 2008; 48:272-280.
Sobieszczyk ME, Talley AK, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Highlights of the 12th Conference on Retroviruses and Opportunistic Infections, 2005. Topics in HIV Medicine. 2005 Mar-April; 13(1):22-44.
Sobieszczyk ME, Hay CM. "Gender-Specific Issues in Non-HIV Viral Infections" in Principles of Gender Specific Medicine. Edited by Marianne J. Lagato Academic Press May 2004.
Sobieszczyk ME, Furuya EY, Kubin CJ, Hay CM. Efficacy and safety of Polymyxin B in the treatment of infections caused by multi-drug resistant Gram-negative organisms. Journal of Antimicrobial Chemotherapy. 2004 Aug; 54(2):566-9.
630 W 168th Street, Box 82
New York, New York 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: firstname.lastname@example.com
Hong Van Tieu, MD, MS
Assistant Professor in Clinical Medicine
University of Pennsylvania, BS, 1996
Mount Sinai School of Medicine, MD, 2001
Columbia University Mailman School of Public Health, MS, 2009
SPECIALTY: HIV epidemiology, HIV biomedical prevention interventions
Dr. Hong Van Tieu isanAssistant Professor inClinical Medicine in the Division of Infectious Diseases at Columbia University, as well as an Associate Member in the Laboratory of Infectious Disease Prevention at the New York Blood Center. During fellowship at Columbia University, she studied immunologic markers to predict and diagnose tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and TB co-infected adults in Thailand. She served as a co-investigator of the New York City site for the HIV Prevention Trials Network (HPTN) 061 study to prevent HIV infection among Black men who have sex with men (MSM). She is a PI of an NIHK01 career development award to study how sexual networks influence HIV risk among MSM in New York City. She is also involved in HIV vaccine studies with the Columbia University HIV Vaccine Trials Unit in collaboration with the New York Blood Center.
Tieu HV, Li X, Donnell D, Vittinghoff E, Buchbinder S, Parente ZG, Koblin BA. Anal Sex Role Segregation and Versatility among Men Who Have Sex with Men: EXPLORE Study. JAIDS 2013: In Press.
Koblin BA, Tieu HV, Frye V. Disparities in HIV/AIDS in Black Men Who Have Sex with Men. Lancet 2012;380:316-8.
Edwards-Jackson N, Phanuphak N, Tieu HV, Chomchey N, Teeratakulpisarn N, Sathienthammawit W, Pakam C, Pharachetsakul N, Sobieszczyk ME, Phanuphak P, Ananworanich J. HIV Serostatus Disclosure is Not Associated with Safer Sexual Behavior among HIV-positive Men Who Have Sex with Men and Their Partners at Risk for Infection in Bangkok, Thailand. AIDS Research and Therapy 2012;9(1):38.doi: 10.1186/1742-6405-9-38.
Tieu HV, Spikes P, Patterson J, Bonner S, Egan JE, Goodman K, Stewart K, Frye V, Xu G, Hoover DR, Koblin BA. Sociodemographic and Risk Behavior Characteristics Associated with Unprotected Sex with Women among Black Men Who Have Sex with Men and Women in New York City. AIDS Care 2012;24(9):1111-9.
Koblin BA, Bonner S, Powell B, Metralexis P, Egan JE, Patterson J, Xu G, Hoover DR, Goodman K, Chin J, Tieu HV, Spikes P. A Randomized Trial of a Behavioral Intervention for Black Men Who Have Sex with Men: The DiSH Study, AIDS 2012;26(4):483-8.
Koblin BA, Mansergh G, Frye V, Tieu HV, Hoover DR, Bonner S, Flores SA, Hudson SM, Colfax GN, Project Mix Study Team. Condom Use Decision Making in the Context of Hypothetical Pre-exposure Prophylaxis Efficacy among Substance-using Men Who Have Sex with Men: Project MIX. JAIDS 2011;58(3):319-27.
Tieu HV, Xu G, Bonner S, Spikes P, Egan JE, Goodman K, Stewart K, Koblin BA. Sexual Partner Characteristics, Serodiscordant/Serostatus Unknown Unprotected Anal Intercourse and Disclosure among HIV-infected and Uninfected Black Men Who Have Sex with Men in New York City. Sexually Transmitted Diseases 2011;38(6):548-54.
Tieu HV, Murrill C, Xu G, Koblin BA. Sexual Partnering and HIV Risk among Black Men Who Have Sex With Men: New York City. Journal of Urban Health 2010;87:113-21.
Tieu HV, Phanuphak N, Ananworanich J, Vatanparast R, Jadwattanakul T, Pharachetsakul N, Mingkwanrungrueng P, Buajoom R, Teeratakulpisarn , Hammer SM, Chiasson MA, Phanuphak P. Acceptability of Circumcision for the Prevention of HIV among High-risk Heterosexual Men in Thailand. Sexually Transmitted Diseases 2010;37:352-5.
Tieu HV, Koblin BA. HIV, Alcohol, and Noninjection Drug Use. Current Opinion in HIV and AIDS 2009;4:314-8.
Manosuthi W, Tieu HV, Tantanathip P, Mankatitham W, Lueangniyomkul A, Ananworanich J, Avihingsanon A, Siangphoe U, Klongugkara S, Thawornwan U, Suntisuklappon B, Sungkanuparph S, for the N2R Study Team. Clinical Case Definition and Manifestations of Paradoxical Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. AIDS 2009;23:2467-71.
Tieu HV, Ananworanich J, Avihingsanon A, Apateerapong W, Sirivichayakul S, Klongugkara S, Boonchokchai B, Siangphoe U, Hammer S, Manosuthi W. Immunologic Markers as Predictors of TB-associated Immune Reconstitution Inflammatory Syndrome in HIV/TB Co-infected Persons in Thailand. AIDS Research and Human Retroviruses 2009;25:1083-9.
Columbia University Medical Center
630 W 168th Street
Box 82
New York, New York 10032
Tel: 212-305-7185 / 212-570-3081
E-mail: firstname.lastname@example.com
NAME: Anne-Catrin Uhlemann, MD, PhD
ACADEMIC TITLE: Assistant Professor of Medicine
Eberhard Karls University, Tubingen, Germany, MD, 1999
Eberhard Karls University, Tubingen, Germany, Dr. med, 1999
University of London, United Kingdom, MS, 2004
University of London, United Kingdom, PhD
SPECIALTY: Internal Medicine and Infectious Diseases
The past decade has witnessed a dramatic increase in Staphylococcus aureus infections acquired from the community. Yet there remains a limited understanding of how these strains spread and subsequently become established and persist within communities.
My research is focused on identifying molecular mechanisms that allow epidemic S. aureus strains such as USA300 to successfully disseminate. This project uses a combined approach of whole-genome comparative sequencing of longitudinally collected samples, genetic manipulation, and functional studies on bacterial adhesion and survival. These molecular studies are informed by ongoing epidemiological studies on S. aureus transmission in the local community. This work has identified a potentially newly emerging S. aureus strain, ST398, which was previously only associated with close contacts to animals. Ongoing studies are aimed at elucidating the molecular mechanisms of its cross-species transfer and current animal-independent spread.
In addition, I maintain an active interest in genetic determinants of drug resistance in the malarial parasite Plasmodium falciparum, following on from my earlier studies in this area.
Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Vancomycin-intermediate Staphylococcus aureus: the contribution of selected gene mutations in clinical isolates. Antimicrob Agents Chemother 2012 (in press).
Miko BA, Uhlemann AC, Gelman A, Lee CJ, Hafer CA, Sullivan SB, Shi Q, Miller M, Zenilman J, Lowy FD. High prevalence of colonization with Staphylococcus aureus clone USA300 at multiple body sites among sexually transmitted disease clinic patients: an unrecognized reservoir. Microbes Infect 2012 Jun 21. [Epub ahead of print].
Uhlemann AC, Fidock DA. Loss of malarial susceptibility to artemisinin in Thailand. Lancet 2012 379(9830):1928-30.
Mediavilla JR, Chen L, Uhlemann AC, Hanson BM, Rosenthal M, Stanak K, Koll B, Fries BC, Armellina D, Schilling ME, Weiss D, Smith TC, Lowy FD, Kreiswirth BN. Human Infection with Methicillin-Susceptible Staphylococcus aureus Clonal Complex 398 in New York City, 2004-2010. Emerg Inf Dis 2012 18(4):700-2.
Uhlemann AC, Dumortier C, Hafer C, Taylor BS, Sanchez-E J, Rodriguez-Taveras C, Leon P, Rojas R, Olive C, Lowy FD. Molecular characterization of Staphylococcus aureus from the Caribbean reveals the presence of pandemic clones. Eur J Clin Micro Infect Dis 2011 31(4):505-11.
Uhlemann AC, Porcella SF, Trivedi S, Sullivan SB, Hafer C, Kennedy AD, Barbian KD, McCarthy AJ, Street C, Hirschberg DL, Lipkin WI, Lindsay JA, Deleo FR, Lowy FD. Identification of a Highly Transmissible Animal-Independent Staphylococcus aureus ST398 Clone with Distinct Genomic and Cell Adhesion Properties. mBio 2012 3(2):pii: e00027-12.
Uhlemann AC, Knox J, Miller M, Hafer C, Vasquez G, Ryan M, Vavagiakis P, Shi Q, Lowy FL. Identification of the environment as an unrecognized reservoir for epidemic community-associated methicillin resistant Staphylococcus aureus USA300. PLos ONE 2011; 6: e22407.
Nair S, Nash D, Sudimack D, Jaidee A, Barends M, Uhlemann AC, Krishna S, Nosten F and Anderson TJ. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol Biol Evol 2007;24:562-73.
Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, Krishna S, White NJ, Nosten F, Price RN. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis. 2007 195(1):134-41.
Jeffares DC, Pain A, Berry A, Cox AV, Stalker J, Ingle CE, Thomas A, Quail MA, Siebenthall K, Uhlemann AC, Kyes S, Krishna S, Newbold C, Dermitzakis ET and Berriman M. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nature Genet 200739:120-5.
Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S and Fidock DA. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 2006;194:528-35.
Price RN, Uhlemann A-C, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ and Nosten F. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006;42:1570-7.
Uhlemann AC, Ramharter M, Lell B, Kremsner PG and Krishna S. Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis 2005;192:1830-5.
Price RN*, Uhlemann AC*, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F and Krishna S. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. The Lancet 2004;364:438-47; *Co-first authors.
Uhlemann A-C, Szlezak NA, Vonthein R, Tomiuk J, Emmer SA, Lell B, Kremsner PG and Kun JF. DNA phasing by TA dinucleotide microsatellite length determines in vitro and in vivo expression of the gp91phox subunit of NADPH oxidase and mediates protection against severe malaria. J Infect Dis 2004;189:2227-34.
Department of Medicine
630 West 168th Street, 9-458
Fax: 212-305-5794
E-mail: email@example.com
Michael Yin, MD, MS
Florence Irving Associate Professor of Clinical Medicine
Princeton University, BA, 1991
Columbia College of Physicians and Surgeons, MD, 1996
Columbia University Mailman School of Public Health, MS (Epidemiology),
SPECIALTY: HIV therapy and metabolic complications
Dr. Yin is the Florence Irving Associate Professor of Medicine in the Division of Infectious Diseases. His primary research focus is on the metabolic complications of HIV infection and antiretroviral therapy. He is the Principal Investigator of a NIAID-funded R01 to examine the effects of the menopausal transition on bone and muscle outcomes in HIV-infected women in the Women's Interagency HIV study (WIHS), utilizing imaging and biomarker techniques, novel in vitro bone precursor cell assays and assessment of muscle mass, quality and functional performance. He is the Co-Principal Investigator of a NICHD-funded R01 to examine bone health in perinatally HIV-infected children on antiretrovirals in South Africa. As a member of the Bone and Metabolic Working Groups for the WIHS, Veterans Aging Cohort Study (VACS) and AIDS Clinical Trials Group (ACTG), Dr. Yin is involved in other studies on bone, fracture, and other metabolic complications in HIV-infected individuals. He is the Co-Chair of ACTG 5280, a study to evaluate whether high dose vitamin D supplementation mitigates the bone loss associated with initiation of antiretroviral therapy in HIV-infected individuals. He is also a site investigator for the HIV Vaccine Trials Network (HVTN) and is Chair of HVTN 404 and Co-chair of HVTN 505.
Shiau S, Broun EC, Arpadi S, Yin MT, Incident fractures in HIV-infected individuals: a systematic review and meta-analysis, AIDS 2013 (in press)
Yin MT, Shu A, Zhang CA, Boutroy S, McMahon DJ, Ferris DC, Colon I, Shane E, "Trabecular and cortical microarchitecture in postmenopausal HIV-infected women," Calcified Tissue International 2013 Mar 5 [Epub ahead of print]
Wright K, Young PC, Brickman C, Sam T, Pereira M, Badjatia N, Connolly ES, Yin MT "Rates and determinants of ventriculostomy-related infections (VRI) during a hospital transition to use of antibiotic-coated external ventricular drains" Neurosurgical Focus 2013 34(5) E12 PMID: 23634916
Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, Glesby MJ, Bolivar H, McComsey GA, "Fractures after antiretroviral initiation: An analysis of the ACTG longitudinal linked randomized trial (ALLRT) study," AIDS 2012 26(17):2175-84
Kubin CJ, Ellman T, Phadke V, Haynes LJ, Calfee DP, Yin MT, "Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy" Journal of Infection 2012; 65(1) 80-7
Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, Cermers S, Shane E "Higher rates of bone loss in postmenopausal HIV-infected women: A longitudinal study" Journal of Clinical Endocrinology and Metabolism 2012 97(2): 554-62
Yin MT, Modarresi R, Shane E, Santiago F, Ferris DC, McMahon DJ, Cremers S, Laurence J, "Effects of HIV infection and antiretroviral therapy with ritonavir on bone turnover and osteoclast induction" Osteoporosis International 2011, 22(5): 1459-68
Yin MT, Shi Q, Hoover DR, Anastos KA, Sharma A, Young M, Levine A, Cohen M, Shane E Golub ET, Tien PC, "Fracture incidence in HIV infected women: results from the Women's HIV Interagency Study" AIDS, 2010 13;24(17):2679-86
Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, Shane E, Golub ET, Anastos K, "Short-term bone loss in HIV-infected premenopausal women" Journal of Acquired Immune Deficiency Syndrome, 2010 53(2): 202-8
Yin MT, McMahon D, Ferris D, Zhang C, Shu A, Staron R, Colon I,Laurence J, Dobkin J, Hammer S, Shane E "Low bone mass and highbone turnover in postmenopausal HIV-infected women" Journal of Clinical Endocrinology and Metabolism 2010; 95(2):620-9
Department of Medicine
Division of Infectious Diseases
630 West 168th Street, Box 82
New York, NY 10032
Tel: 212-305-7185
Fax: 212-305-7290
E-mail: firstname.lastname@example.com
to Top